---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence. Covers RAPIDe-3, RAPIDe-1, RAPIDe-2, and PHA121-C001. 273 evidence topics quoted from 40 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 RAPIDe-3

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Trial aim

> “The RAPIDe-3 phase 3 trial aimed to assess the efficacy and safety of oral deucrictibant immediate-release capsule for on-demand treatment of attacks in adolescents and adults with hereditary angioedema.”
> “Our phase 3 trial was carried out to confirm the efficacy and safety of deucrictibant in a larger patient population in all subtypes of hereditary angioedema, including those with normal C1 inhibitor.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.1-2"></a>

###### Registry brief summary

> “This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 2-period, 2-treatment cross-over study to evaluate the efficacy and safety of orally administered deucrictibant compared to placebo for the on-demand treatment of HAE attacks, including non-severe laryngeal attacks, in participants ≥12 to ≤75 years of age with HAE type 1, type 2, or type 3, a proportion of whom are using long-term prophylactic medication for HAE.”

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

<a id="topic-3.1.1.1-3"></a>

###### Objective stated in the AAAAI 2026 results poster

> “To assess the efficacy, safety, and tolerability of oral deucrictibant immediate-release (IR) capsule for on-demand treatment of attacks in adolescents and adults with HAE, including participants with HAE with normal C1 inhibitor (HAE-nC1INH).”

Source: [Riedl et al. (2026a)](https://ir.pharvaris.com/static-files/39c3dc39-68f9-4cd9-b814-63bddfe7255b)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Sites, countries, and enrollment period in the publication

> “The trial was conducted at 59 sites across 24 countries on six continents”
> “Between April 4, 2024, and Sept 1, 2025, 149 people were assessed for eligibility”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.2-2"></a>

###### Countries in each geographical region

> “Geographical region of North America includes Canada, Puerto Rico, and the USA; Europe includes Austria, Bulgaria, Czech Republic, France, Germany, Hungary, Italy, the Netherlands, Poland, Spain, Sweden, and the UK; rest of world includes Argentina, Australia, Brazil, Hong Kong, Japan, Saudi Arabia, South Africa, South Korea, and Türkiye.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.2-3"></a>

###### Patient association input on countries and sites

> “A global network of patient associations provided recommendations of countries, potential study sites, and study investigators.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.2-4"></a>

###### Registry dates, status, and number of locations

> “Study Start (Actual) 2024-02-26 Primary Completion (Actual) 2025-10-17 Study Completion (Actual) 2025-10-17”
> “This study has 76 locations”

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

<a id="topic-3.1.1.2-5"></a>

###### Trial initiation and topline timing reported by the company

> “Following the readout of RAPIDe-2, we initiated RAPIDe-3, a global, pivotal Phase 3, placebo-controlled study to evaluate deucrictibant IR capsule (20 mg) for the on-demand treatment of attacks in people 12 years and older with HAE, in March 2024 and reported topline data in December 2025.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-3.1.1.2-6"></a>

###### Target enrollment reached

> “reached target enrollment in March 2025”

Source: [Pharvaris Form 6-K, first quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000095017025070308/phvs-ex99_1.htm)

<a id="topic-3.1.1.2-7"></a>

###### Topline announcement date

> “ZUG, Switzerland, December 3, 2025 – Pharvaris (Nasdaq: PHVS)”
> “today announced RAPIDe-3 pivotal data confirming the potential of deucrictibant’s differentiated profile for the on-demand treatment of HAE attacks.”

Source: [Pharvaris RAPIDe-3 topline press release (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000119312525305951/d69798dex991.htm)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Crossover design, randomization, and stratification

> “The trial was conducted using a randomised, double-blind, two-period, two-sequence crossover design (2 × 2 crossover) comparing deucrictibant with placebo.”
> “All participants were randomly allocated 1:1 to one of two double-blind crossover sequences of deucrictibant–placebo or placebo–deucrictibant to treat two qualifying attacks (figure 1; appendix p 17), stratified by age (≥12 to <18 years or ≥18 years) and concomitant long-term prophylaxis use at the time of screening (yes or no).”
> “Randomisation of treatment sequence assignment was done via an interactive response technology system.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.3-2"></a>

###### Masking and study drug packaging

> “Participants, investigators, site personnel, and the sponsor were masked to treatment assignment.”
> “Each wallet contained one single capsule (either deucrictibant or placebo).”
> “Wallets and capsules of deucrictibant and placebo were identical to maintain masking.”
> “Treatment unmasking was permitted in the case of emergency as determined by the investigator.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.3-3"></a>

###### Washout between treated attacks

> “Following attack treatment with study drug (or after the second dose of study drug or conventional rescue medication, if used), a washout period of at least 72 h before treatment of the next attack with study drug was required to avoid potential carry-over effects.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.3-4"></a>

###### Non-attack pharmacokinetic dose in adolescents

> “Before random allocation, adolescent participants received a single oral deucrictibant capsule in a non-attack state for pharmacokinetic assessment.”
> “The pharmacokinetic profile of deucrictibant immediate-release capsule in adults was previously described.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.3-5"></a>

###### Electronic patient-reported outcomes and attack qualification by the investigator

> “All participants used a handheld device to record electronic patient-reported outcomes (ePRO) for attack symptom ratings and other attack-related information, including study drug intake and rescue medication use.”
> “Participants first entered their attack information into the ePRO device. Each attack was then assessed and qualified by the investigator during a telephone call or other live communication.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.3-6"></a>

###### Registry design details

| Field | Reported value |
| --- | --- |
| Other study ID number | “PHA022121-C306” |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Crossover Assignment” |
| Masking | “Quadruple” |

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

<a id="topic-3.1.1.3-7"></a>

###### Registry study phases

> “The study consists of a Screening Phase during which eligibility is confirmed, a Treatment Phase in which participants will be randomized and receive double blinded study drug to treat 2 qualifying HAE attacks (i.e., 2 Treatment Periods within the Treatment Phase), and an End-of-Study Follow-up Phase after the second attack treated with study drug.”

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

<a id="topic-3.1.1.3-8"></a>

###### Optional rollover to the open-label extension

> “Data from end-of-study visit could be used to qualify the participant for an OLE study with deucrictibant.”
> “Rollover to the OLE was optional.”

Source: [Anderson et al. (2026c)](https://ir.pharvaris.com/static-files/9d17729a-c3ad-4b4b-a355-40e360776318)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Inclusion criteria in the publication

> “Adolescents (aged ≥12 to <18 years) and adults (aged ≥18 to ≤75 years) with hereditary angioedema, including those with normal C1 inhibitor associated with a documented genetic variant, at least two attacks within the last 3 months before screening, and experience with effectively using conventional on-demand therapies for hereditary angioedema attacks were eligible.”
> “Participants using concomitant hereditary angioedema long-term prophylaxis were also eligible.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.4-2"></a>

###### Exclusion criteria in the publication

> “Participants were excluded in cases of any diagnosis of other forms of angioedema or previous on-demand hereditary angioedema treatment with deucrictibant.”
> “Pregnant and breastfeeding women were not eligible.”
> “Women of childbearing potential were eligible if sexually abstinent or using medically acceptable contraception.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.4-3"></a>

###### Registry inclusion criteria

> “Male or female, aged ≥12 to ≤75 years at the time of providing written informed consent/assent.”
> “Diagnosis of HAE-1/2/3.”
> “History of at least 2 HAE attacks in the last 3 months before screening.”
> “Experience with using standard-of-care treatment to effectively manage on-demand treatment for HAE attacks.”
> “Participants on long-term prophylactic therapy with plasma-derived C1-INH (danazol, anti-fibrinolytics, berotralstat, or lanadelumab) must be on a stable dose and regimen and intend to remain on the same dose for 6 months before screening and the duration of the study.”
> “For adolescent participants aged ≥12 and <18 years of age: body weight ≥40 kg.”

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

<a id="topic-3.1.1.4-4"></a>

###### Registry exclusion criteria: organ function, CYP3A4 medicines, and prior therapies

> “Use of attenuated androgens for short-term prophylaxis within 2 weeks before screening.”
> “Abnormal hepatic function.”
> “Abnormal renal function (eGFR <60 ml/min/1.73 m2).”
> “Has received prior on-demand HAE treatment with deucrictibant.”
> “Prior gene therapy for any indication at any time.”
> “Use of concomitant medications with systemic absorption that are strong inhibitors of CYP3A4 or strong inducers of CYP3A4 within the last 30 days, or within 5 half-lives (whichever is longer) of the time of randomization.”

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

<a id="topic-3.1.1.4-5"></a>

###### Qualifying attacks and exclusion of severe laryngeal attacks

> “Qualifying attacks were defined as either non-laryngeal attacks, with at least one symptom item score of 20 or more on the angioedema symptom rating scale (AMRA) assessment, which measures skin swelling, skin pain, and abdominal pain, as described below, or non-severe laryngeal attacks without breathing difficulties or stridor.”
> “Attacks of any severity (mild, moderate, and severe) were included, barring severe laryngeal attacks, consistent with other recent phase 3 trials of on-demand treatment in hereditary angioedema,”
> “due to the risks of random assignment to treatment with double-masked placebo.”
> “Adolescent participants with laryngeal attacks, regardless of severity, and adult participants with severe laryngeal attacks (those with symptoms of breathing difficulties or stridor) were instructed to immediately take their conventional on-demand therapy instead of the study drug and to seek medical care urgently.”
> “Attacks that did not meet the qualification criteria were treated with conventional on-demand therapy.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Study drug and dose

> “The RAPIDe-3 phase 3, randomised, double-blind, placebo-controlled crossover trial evaluated the efficacy and safety of oral deucrictibant immediate-release capsule 20 mg (henceforth referred to as deucrictibant).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.5-2"></a>

###### Registry treatment sequences and intervention

> “Deucrictibant administered for first HAE attack, placebo administered for second HAE attack.”
> “Placebo administered for first HAE attack, deucrictibant administered for second HAE attack.”
> “Deucrictibant Soft Capsules for Oral Use”

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

<a id="topic-3.1.1.5-3"></a>

###### Self-administration after investigator qualification

> “Following investigator-confirmed qualification and before administration of the study drug, participants completed their pre-treatment assessments, including PGI-S and AMRA ratings, using the ePRO instruments on the electronic device.”
> “During the qualification call with the investigator or immediately following, patients then self-administered the study drug.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.5-4"></a>

###### Second capsule and rescue medication rules

> “If symptoms persisted or progressed, a second capsule of the same study drug was permitted 4 h or later after the first capsule, and conventional on-demand therapy as rescue medication was permitted 1 h or more after the second capsule for non-laryngeal attacks.”
> “For laryngeal attacks, a second capsule of study drug was not permitted, and rescue medication was allowed at any time.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.5-5"></a>

###### Registry definition of rescue medication

> “Rescue medication is defined as the participant's usual acute on-demand HAE treatment taken if symptoms persist or progress after study drug administration.”

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Time to Onset of Symptom Relief by Patient Global Impression of Change as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Primary endpoint: definition in the publication

> “The primary endpoint was time to onset of symptom relief, defined as achieving a rating of at least a little better on the PGI-C scale for two consecutive timepoints within 12 h post-treatment.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.6.1-2"></a>

###### Primary endpoint: registry definition and time frame

> “Time to onset of symptom relief, defined as Patient Global Impression of Change (PGI-C) rating of at least "a little better" for 2 consecutive timepoints within 12 hours post-treatment.”
> “The PGI-C (7-point scale) is used to evaluate the change in the HAE attack symptoms as compared to pre-treatment.”
> “Pre-treatment to 12 hours post-treatment.”

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

<a id="topic-3.1.1.6.1-3"></a>

###### PGI-C and PGI-S scales

> “The Patient Global Impression of Change (PGI-C) was used to evaluate the change in the hereditary angioedema attack symptoms at the time of the assessment compared with pre-treatment (last symptom assessment before study drug administration) and was scored on a seven-point Likert scale with possible responses of much better, better, a little better, same, a little worse, worse, and much worse.”
> “The Patient Global Impression of Severity (PGI-S) was used to evaluate the severity of hereditary angioedema attack symptoms at the time of the assessment and was scored on a five-point Likert scale with possible responses of none, mild, moderate, severe, and very severe.”
> “The PGI-C and PGI-S are validated instruments for evaluating patient-reported outcomes that have been previously used in clinical trials in hereditary angioedema to evaluate a patient's global perception of changes in and severity of their attack manifestations, respectively.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.6.1-4"></a>

###### Assessment schedule after study drug

> “Following study drug administration, patients completed the PGI-C, the PGI-S, and AMRA assessments using the ePRO device at 15 min and 30 min post-treatment, then every 30 min through to 4 h, every 60 mins through to 12 h, every 120 mins through to 24 h, and at 36 h and 48 h post-treatment.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.6.1-5"></a>

###### Selection of PGI-C for the primary endpoint: mixed methods patient-reported outcome study

> “When comparing different definitions of time to onset of symptom relief, PGI-C had greater sensitivity in detecting early symptom relief yet remained comparable to AMRA symptom relief endpoints.”
> “For the PGI-C, participants (n = 19) discussed perceived meaningful improvement from their worst score and associated this with a reduction or improvement in symptoms and knowledge the attack would not worsen.”
> “On the basis of the association between AMRA and PGI-C established in this study, the phase 3 RAPIDe-3 trial used the PGI-C to define the primary efficacy endpoint.”

Source: [Mendivil et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12953491/)

<a id="topic-3.1.1.6.1-6"></a>

###### PGI-C rating of a little better as a clinically meaningful milestone: patient interviews and phase 2 sebetralstat data

> “Patient interviews revealed a strong preference (71%) for the Patient Global Impression of Change (PGI‐C) over other measures and indicated a rating of "A Little Better" as a clinically meaningful milestone.”
> “Feedback from a patient advisory board initially identified the PGI‐C as a preferred PRO for assessing symptom relief in HAE, and follow‐up structured interviews highlighted that the rating of "A Little Better" on the PGI‐C best represented the earliest signs of symptom relief for most patients.”

Source: [Cohn et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10476273/)

<a id="topic-3.1.1.6.1-7"></a>

###### Core outcome set for trials of acute treatment

> “In the second round, a consensus of 90% or greater was achieved on a core outcome set consisting of five key outcomes: change in overall symptom severity at one predetermined time point between 15 minutes and 4 hours after treatment, time to end of progression of all symptoms, the need for rescue medication during the entire attack, impairment of daily activities, and treatment satisfaction.”

Source: [Petersen et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38609017/)

<a id="topic-3.1.1.6.1-8"></a>

###### Conformance of RAPIDe-3 endpoints with the AURORA core outcome set

> “To investigate deucrictibant further, we conducted a phase 3 trial with prespecified endpoints conforming to the set of core outcomes recommended for inclusion in on-demand treatment trials by the recent AURORA Delphi Consensus, which were developed with input from patients with hereditary angioedema, and included measurement of changes in symptom severity, end of progression, and duration of treatment response based on need for additional treatment.”
> “Additionally, to the best of our knowledge, this is the first and only trial with prespecified endpoints designed to conform to all core outcomes recommended for inclusion in on-demand hereditary angioedema trials by the recent international AURORA Delphi Consensus.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.6.1-9"></a>

###### Key secondary endpoints: definitions in the publication

> “Secondary efficacy endpoints were measured using the PGI-C, PGI-S, and AMRA instruments, and included: proportion of study drug-treated attacks reaching onset of symptom relief at 4 h (PGI-C), time to substantial symptom relief, defined as the time to a PGI-C rating of at least better for two consecutive timepoints within 12 h post-treatment, reduction in attack severity within 12 h (PGI-S), complete symptom resolution within 48 h (PGI-S), end of progression of symptoms within 12 h (PGI-C and AMRA), substantial symptom relief defined as time to 50% or greater reduction in AMRA composite score from pre-treatment for two consecutive timepoints within 12 h post-treatment, and almost complete or complete symptom resolution within 24 h (AMRA).”
> “Remaining secondary endpoints were the proportion of attacks achieving almost complete or complete symptom resolution within 24 h (AMRA), the proportion of attacks reaching complete symptom resolution with one capsule (PGI-S), and the proportion of attacks using rescue medication.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.6.1-10"></a>

###### Key secondary endpoints: first six in the testing hierarchy

> “The primary and first 6 of 11 hierarchical order-ranked secondary endpoints.”

Source: [Riedl et al. (2026a)](https://ir.pharvaris.com/static-files/39c3dc39-68f9-4cd9-b814-63bddfe7255b)

| Secondary endpoint | Definition |
| --- | --- |
| “Proportion of attacks achieving onset of symptom relief” | “Proportion of study-drug treated attacks achieving a PGI-C rating of at least "a little better" at 4 hours post-treatment” |
| “Time to substantial symptom relief” | “Time to a PGI-C rating of at least "better" for 2 consecutive timepoints within 12 hours post-treatment” |
| “Time to reduction in attack severity” | “Time to a ≥1-level reduction in PGI-S score from pre-treatment for 2 consecutive timepoints within 12 hours post-treatment” |
| “Time to complete symptom resolution” | “Time to PGI-S rating of "none" within 48 hours post-treatment” |
| “Time to end of progression” | “Time to the earliest post-treatment timepoint after which all subsequent PGI-C ratings are stable or improved within 12 hours” |
| “Use of conventional on-demand treatment as rescue medication” | “Proportion of study-drug treated attacks using conventional on-demand treatment as rescue medication to treat an attack within 24 hours post-treatment” |

Source: [Riedl et al. (2026a)](https://ir.pharvaris.com/static-files/39c3dc39-68f9-4cd9-b814-63bddfe7255b)

<a id="topic-3.1.1.6.1-11"></a>

###### Key secondary endpoints: registry definitions

| Outcome measure | Measure description |
| --- | --- |
| “Proportion of study drug-treated attacks achieving PGI-C rating of at least "a little better" at 4 hours post-treatment.” | “The PGI-C (7-point scale) is used to evaluate the change in the HAE attack symptoms as compared to pre-treatment.” |
| “Time to substantial symptom relief, defined as achieving PGI-C rating of at least "better" for 2 consecutive timepoints within 12 hours post-treatment.” | “The PGI-C (7-point scale) is used to evaluate the change in the HAE attack symptoms as compared to pre-treatment.” |
| “Time to substantial symptom relief by Patient Global Impression of Severity (PGI-S).” | “Defined as achieving ≥1 point reduction in PGI-S (5-point scale) from pre-treatment for 2 consecutive timepoints within 12 hours post-treatment.” |
| “Time to complete symptom resolution, defined as achieving PGI-S rating of "none" within 48 hours post-treatment.” | “The PGI-S (5-point scale) is used to evaluate the severity of HAE attack symptoms.” |
| “Time to End of Progression (EoP) in attack symptoms within 12 hours.” | “EoP time defined as the earliest post-treatment timepoint after which all subsequent PGI-C ratings are stable or improved.” |
| “Proportion of study drug-treated attacks requiring rescue medication within 24 hours post-treatment.” | “Rescue medication is defined as the participant's usual acute on-demand HAE treatment taken if symptoms persist or progress after study drug administration.” |
| “Proportion of attacks achieving symptom resolution.” | “Defined as achieving PGI-S rating of "none" with one dose of study drug at 24 hours post-treatment.” |
| “Time to substantial symptom relief by Angioedema Symptom Rating Scale (AMRA).” | “Defined as a ≥50% reduction in AMRA composite score from pre-treatment for 2 consecutive timepoints within 12 hours post-treatment.” |
| “Time to almost complete or complete symptom relief by AMRA.” | “Defined as all item scores in AMRA having a value ≤10 for 2 consecutive timepoints within 24 hours post-treatment.” |
| “Proportion of study drug-treated attacks reaching almost complete or complete symptom relief by AMRA.” | “Defined as all item scores in AMRA having a value ≤10 at 24 hours post-treatment.” |
| “Time to EoP in attack symptoms within 12 hours.” | “Defined as the earliest post-treatment timepoint after which every individual AMRA item is stable or improved at all subsequent timepoints.” |

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

<a id="topic-3.1.1.6.1-12"></a>

###### Key secondary endpoint: end of progression, definition and rationale

> “End of progression (EoP): defined as the earliest post-treatment timepoint after which attack manifestations stop worsening further, which marks the earliest evidence of treatment effects.”
> “It can serve as a clinically meaningful indicator of attacks starting to evolve toward relief and resolution.”
> “Achieving EoP can also offer psychological reassurance by reducing the uncertainty associated with HAE attack escalation.”

Source: [Anderson et al. (2026c)](https://ir.pharvaris.com/static-files/9d17729a-c3ad-4b4b-a355-40e360776318)

> “To our knowledge, the inclusion of end of progression of symptoms measured in RAPIDe-3 as a prespecified endpoint, marking the earliest evidence of treatment effects, is the first instance in a hereditary angioedema on-demand trial.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.6.1-13"></a>

###### Key secondary endpoint: end of progression, psychometric validation with RAPIDe-3 data

> “Psychometric analyses of patient-reported outcomes from the Phase 3 RAPIDe-3 trial collectively support the validity of a Patient Global Impression of Change (PGI-C)–based definition of end of progression (EoP) of hereditary angioedema (HAE) attack symptoms based on the Patient Global Impression of Severity (PGI-S) and three-item Angioedema syMptom Rating scAle (AMRA-3) as anchor measures.”
> “Analyses were performed for a total of 194 attacks (192 non-laryngeal and 2 laryngeal).”
> “PGI-C was strongly associated with latent changes in HAE severity (β = 0.824), explaining 68% of variance in PGI-C; these findings support the use of PGI-C as a valid instrument for evaluating EoP.”
> “Within-person correlations between PGI-C and change in PGI-S (correlation for repeated measures, rrm = 0.765) and between PGI-C and percent change in AMRA-3 (rrm = 0.839) exceeded the 0.30 threshold required for use as anchors (Table 4).”

Source: [Cohn et al. (2026)](https://ir.pharvaris.com/static-files/8ea05186-a535-4842-bb06-c31a4994fbea)

<a id="topic-3.1.1.6.1-14"></a>

###### Key secondary endpoints measured with the angioedema symptom rating scale

> “The AMRA was adapted from the visual analogue scale (VAS), which had been previously used in earlier clinical trials of on-demand treatments for hereditary angioedema, to measure symptom severity at the time of the assessment on a scale from 0 (no symptoms) to 100 (worst possible symptoms).”
> “VAS-3 symptom and VAS 5-symptom assessments have since been adapted into electronic versions and renamed AMRA-3 and AMRA-5, respectively.”
> “AMRA-3, which rates the severity of three key attack symptoms (skin pain, skin swelling, and abdominal pain) was used to evaluate non-laryngeal attacks. AMRA-5, which additionally includes the symptoms of voice change and difficulty swallowing, was used to evaluate laryngeal attacks.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.6.1-15"></a>

###### Safety endpoints and the 3-day reporting window

> “Safety endpoints were incidence of treatment-emergent adverse events and of treatment-emergent serious adverse events, and change from baseline in clinical laboratory findings, vital signs, and electrocardiogram parameters.”
> “Due to the duration of exposure to deucrictibant following administration of the immediate-release capsule (8 h or longer), treatment-emergent adverse events reported within 3 days of study drug administration were considered temporally clinically relevant.”
> “A treatment-emergent adverse event was defined as an adverse event from the first study drug administration through to the end of study visit.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Sample size calculation and planned enrollment

> “Assuming median time to onset of symptom relief of 2 h for deucrictibant and 5 h for placebo, and a within-participant correlation of 0·2, statistical simulations indicated that a total of 60 participants in the primary efficacy analysis set would provide at least 90% power to detect a treatment difference in time to onset of symptom relief by PGI-C at a two-sided significance level of 0·05.”
> “Accounting for participants who would not treat an attack in each of the two attack periods, the study planned to enrol approximately 120 participants to achieve the target of at least 60 participants in the primary efficacy analysis set (two treated attacks, one per crossover period).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.7.1-2"></a>

###### Planned enrollment stated by the company, May 2025

> “RAPIDe-3, a pivotal global Phase 3 study evaluating deucrictibant immediate-release capsule (20 mg) for the on-demand treatment of HAE attacks in adults and adolescents (12 years and older), reached target enrollment in March 2025; the study continues to assess HAE attacks in approximately 120 participants.”

Source: [Pharvaris Form 6-K, first quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000095017025070308/phvs-ex99_1.htm)

<a id="topic-3.1.1.7.1-3"></a>

###### Registry actual enrollment

> “Enrollment (Actual) 134”

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

<a id="topic-3.1.1.7.1-4"></a>

###### Participants and attacks analyzed in each analysis set

> “The primary efficacy analysis set included 88 participants who had one deucrictibant-treated and one placebo-treated attack, for a total of 176 attacks (appendix p 23).”
> “Prespecified sensitivity analyses, including treatment effect estimates, were done for all 113 participants with at least one study drug-treated attack, for a total of 201 attacks.”
> “N refers to the total number of participants with at least one dose of study drug.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.7.1-5"></a>

###### Safety analysis set by treatment received

> “Data based on Safety Analysis Set, which includes all enrolled participants who received any dose of study drug.”
> “One participant randomized to the deucrictibant-placebo sequence was incorrectly administered placebo for the first attack; study closure occurred before the participant experienced a second attack.”

Source: [Pharvaris RAPIDe-3 topline data presentation (2025)](https://ir.pharvaris.com/static-files/30661839-e400-44eb-a1e9-9ad88f75d404)

<a id="topic-3.1.1.7.1-6"></a>

###### Observed placebo response compared with the sample size assumption

> “The median time to onset of symptom relief in the placebo group was longer than assumed in the sample size calculation as the planning assumption was intentionally conservative and derived from the phase 2 RAPIDe-1 trial using endpoint mapping results from the endpoint validation study.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Primary efficacy, expanded, and safety analysis sets

> “Following the statistical analysis plan, primary efficacy analyses for both time-to-event and binary endpoints were conducted using the primary efficacy analysis set, comprising all randomised participants who treated both attacks with study drug in accordance with the 2 × 2 crossover design.”
> “Sensitivity and subgroup analyses employed an expanded analysis set including all participants who treated at least one attack with study drug, as these analyses did not require within-participant paired comparisons and the broader inclusion mitigated potential sample size limitations in subgroup evaluations.”
> “Safety analyses included all participants who received at least one dose of study drug; comparisons are descriptive.”
> “Summaries and analyses using the primary efficacy analysis set and the set of all participants with at least one treated attack were based on planned treatment. Summaries and analyses using the safety analysis set were based on actual treatment.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.7.2-2"></a>

###### Statistical tests for time-to-event and binary endpoints

> “Time-to-event endpoints were primarily evaluated using the prespecified Gehan's generalised Wilcoxon test, which provided a robust, non-parametric, paired comparison.”
> “Time-to-event endpoint medians were estimated for deucrictibant and placebo, respectively, using the Kaplan–Meier method.”
> “Prespecified sensitivity analyses included linear mixed-effects models applied to Gehan score-transformed event times and marginal Cox proportional hazards model with robust variance estimation.”
> “Binary endpoints were primarily evaluated using the Prescott test, a non-parametric paired comparison method used for 2 × 2 crossover designs.”
> “Prespecified sensitivity analyses were performed using generalised estimating equation models with a logit link.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.7.2-3"></a>

###### Multiplicity control by fixed-sequence gatekeeping

> “Formal hierarchical statistical testing was performed on the primary and secondary efficacy endpoints.”
> “A gatekeeping procedure was used to control study-wise type 1 error rate at a two-sided alpha of 0·05 across all endpoints tested, following the order of first testing the primary endpoint, then the secondary endpoints in the fixed order as predefined in the trial protocol and statistical analysis plan (appendix).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.7.2-4"></a>

###### Intercurrent events and missing data: composite variable strategy

> “An intercurrent event was defined as the use of rescue medication or selected prohibited medication after an attack was treated with study drug.”
> “Intercurrent events were handled using a composite variable strategy for the primary and secondary endpoints that considered intercurrent events a treatment failure.”
> “For such attacks, time-to-event endpoints were right censored at the end of the data collection window for the relevant timeframe, and binary endpoints were classified as unfavourable outcomes, regardless of whether rescue or prohibited medication use occurred before or after the endpoint was reached.”
> “Missing data at the end of follow-up were addressed through right censoring instead of imputation, consistent with the prespecified estimand and survival analysis principles.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.7.2-5"></a>

###### Supplementary analyses: per-protocol set and treatment policy strategy

> “Prespecified supplementary analyses on the primary endpoint included an analysis using the per-protocol analysis set and an analysis using a treatment policy strategy approach on the primary efficacy analysis set and on the set of all participants with at least one treated attack.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Screening, randomization, and treated attacks

> “Between April 4, 2024, and Sept 1, 2025, 149 people were assessed for eligibility, and 134 eligible participants (ten [7%] adolescents and 124 [93%] adults) were enrolled and randomly allocated at 59 sites across 24 countries on six continents (figure 1; appendix p 22).”
> “113 participants treated 201 attacks. The primary efficacy analysis included 88 participants with paired treated attacks.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.1-2"></a>

###### Randomized sequences and attacks treated in each sequence

> “N=134 enrolled (124 adults, 10 adolescents)”
> “N=68 randomized to placebo”
> “N=53 treated one attack with placebo”
> “N=41 treated one attack with deucrictibant”
> “N=66 randomized to deucrictibant”
> “N=60 treated one attack with deucrictibant”
> “N=47 treated one attack with placebo”
> “N=88 paired attacks (Primary Efficacy Analysis Set)”

Source: [Pharvaris RAPIDe-3 topline data presentation (2025)](https://ir.pharvaris.com/static-files/30661839-e400-44eb-a1e9-9ad88f75d404)

<a id="topic-3.1.1.8.1-3"></a>

###### Trial closure before all participants treated two attacks

> “The sponsor ended the trial after the prespecified number of participants with paired treated attacks was met and allowed participants to transition to the open-label extension (NCT05396105) before all participants completed treatment of two attacks.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.1-4"></a>

###### Protocol deviations

> “There were no protocol amendments or deviations from the protocol that affected statistical analysis conclusions (appendix p 24), as evidenced by consistency of the outcomes from the sensitivity and supplemental analyses with the prespecified per-protocol analyses.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### All randomized participants: sex, age, and HAE with normal C1 inhibitor

> “For the 134 eligible participants, 58 (43%) were male and 76 (57%) were female, and the median age was 38·0 years (IQR 27·0–50·0).”
> “Of the four (3%) participants with hereditary angioedema with normal C1 inhibitor, two carried a variant in the plasminogen gene and two carried a variant in the coagulation factor XII gene.”
> “Of the 113 participants who treated at least one attack, 26 (23%) were receiving long-term prophylaxis at enrolment and during the study.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.2-2"></a>

###### All randomized participants: demographic and disease characteristics, 134 participants

| Characteristic | All randomized participants (N=134) |
| --- | --- |
| Age in years, mean (SD) | “39.0 (14.7)” |
| Age ≥12 to <18 years, n (%) | “10 (7.5)” |
| Age ≥18 to <65 years, n (%) | “116 (86.6)” |
| Age ≥65 years, n (%) | “8 (6.0)” |
| Female, n (%) | “76 (56.7)” |
| BMI, mean (SD) | “26.5 (5.9)” |
| White, n (%) | “93 (69.4)” |
| Asian, n (%) | “19 (14.2)” |
| Black or African American, n (%) | “10 (7.5)” |
| Europe, n (%) | “56 (41.8)” |
| Rest of world, n (%) | “40 (29.9)” |
| North America, n (%) | “38 (28.4)” |
| Years since HAE diagnosis, mean (SD) | “17.7 (13.0)” |
| Attacks within 3 months before screening, mean (SD) | “4.4 (3.3)” |
| HAE-C1INH type 1, n (%) | “118 (88.1)” |
| HAE-C1INH type 2, n (%) | “10 (7.5)” |
| Unspecified HAE-C1INH type 1 or 2, n (%) | “2 (1.5)” |
| HAE-nC1INH, n (%) | “4 (3.0)” |
| Current long-term prophylaxis use, n (%) | “31 (23.1)” |

Source: [Riedl et al. (2026a)](https://ir.pharvaris.com/static-files/39c3dc39-68f9-4cd9-b814-63bddfe7255b)

> “LTP medication includes lanadelumab (13 [9.7%]), berotralstat (8 [6.0%]), complement c1 esterase inhibitor (6 [4.5%]), and other (4 [3.0%]).”

Source: [Riedl et al. (2026a)](https://ir.pharvaris.com/static-files/39c3dc39-68f9-4cd9-b814-63bddfe7255b)

<a id="topic-3.1.1.8.2-3"></a>

###### Participants with at least one treated attack: demographic and disease characteristics by treatment, 113 participants

> “Demographics and baseline characteristics of participants with at least one treated attack”
> “Participants may be represented in multiple columns.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

| Characteristic | Deucrictibant (n=101) | Placebo (n=100) | Overall (n=113) |
| --- | --- | --- | --- |
| Age, years, median (IQR) | “36·0 (27·0–49·0)” | “36·5 (28·0–50·0)” | “36·0 (27·0–50·0)” |
| Male | “46 (46%)” | “46 (46%)” | “51 (45%)” |
| Female | “55 (54%)” | “54 (54%)” | “62 (55%)” |
| White | “70 (69%)” | “70 (70%)” | “80 (71%)” |
| Asian | “17 (17%)” | “16 (16%)” | “17 (15%)” |
| Black or African American | “4 (4%)” | “6 (6%)” | “6 (5%)” |
| North America | “21 (21%)” | “26 (26%)” | “28 (25%)” |
| Europe | “47 (47%)” | “41 (41%)” | “50 (44%)” |
| Rest of world | “33 (33%)” | “33 (33%)” | “35 (31%)” |
| BMI, kg/m2, median (IQR) | “25·2 (22·3–28·2)” | “25·6 (22·5–29·2)” | “25·5 (22·4–28·9)” |
| HAE-C1INH-type 1 | “90 (89%)” | “91 (91%)” | “102 (90%)” |
| HAE-C1INH-type 2 | “8 (8%)” | “8 (8%)” | “8 (7%)” |
| HAE-nC1INH | “2 (2%)” | “0” | “2 (2%)” |
| Unspecified HAE-C1INH type 1 or 2 | “1 (1%)” | “1 (1%)” | “1 (1%)” |
| Time since diagnosis, years, median (IQR) | “15·0 (7·0–24·0)” | “15·5 (7·0–24·5)” | “15·0 (7·0–24·0)” |
| Concomitant long-term prophylaxis: yes | “20 (20%)” | “24 (24%)” | “26 (23%)” |
| Long-term prophylaxis: lanadelumab | “8 (8%)” | “10 (10%)” | “11 (10%)” |
| Long-term prophylaxis: berotralstat | “5 (5%)” | “7 (7%)” | “7 (6%)” |
| Long-term prophylaxis: C1-esterase inhibitor | “4 (4%)” | “5 (5%)” | “5 (4%)” |
| Long-term prophylaxis: danazol | “3 (3%)” | “2 (2%)” | “3 (3%)” |
| Attacks in the 3 months before screening: 2–5 | “72 (71%)” | “71 (71%)” | “83 (73%)” |
| Attacks in the 3 months before screening: 6–10 | “19 (19%)” | “19 (19%)” | “20 (18%)” |
| Attacks in the 3 months before screening: 11–15 | “6 (6%)” | “6 (6%)” | “6 (5%)” |
| Attacks in the 3 months before screening: 16–20 | “2 (2%)” | “2 (2%)” | “2 (2%)” |

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.2-4"></a>

###### Primary efficacy analysis set: demographic and disease characteristics, 88 participants

> “Of these, 47 (53%) participants were female and 41 (47%) were male, and 60 (68%), 16 (18%), 4 (5%), and 1 (1%) were White, Asian, Black, and American Indian or Alaska Native, respectively.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

| Characteristic | Primary efficacy analysis group (N=88) |
| --- | --- |
| Age in years, mean (SD) | “38.7 (13.6)” |
| Age ≥12 to <18 years, n (%) | “5 (5.7)” |
| Age ≥18 to <65 years, n (%) | “80 (90.9)” |
| Age ≥65 years, n (%) | “3 (3.4)” |
| Female, n (%) | “47 (53.4)” |
| North America, n (%) | “19 (21.6)” |
| Europe, n (%) | “38 (43.2)” |
| Rest of world, n (%) | “31 (35.2)” |
| Years since HAE diagnosis, mean (SD) | “17.3 (12.24)” |
| HAE-C1INH type 1, n (%) | “79 (89.8)” |
| HAE-C1INH type 2, n (%) | “8 (9.1)” |
| Unspecified HAE-C1INH type 1 or 2, n (%) | “1 (1.1)” |
| Current long-term prophylaxis use, n (%) | “18 (20.5)” |

Source: [Anderson et al. (2026c)](https://ir.pharvaris.com/static-files/9d17729a-c3ad-4b4b-a355-40e360776318)

<a id="topic-3.1.1.8.2-5"></a>

###### Attack type, location, and severity at pre-treatment, 201 treated attacks

> “Of all 201 attacks treated with study drug, 181 (90%) were treated by participants with hereditary angioedema type 1, 16 (8%) by participants with hereditary angioedema type 2, and two (1%) by participants with normal C1 inhibitor (both carrying a variant in the plasminogen gene), respectively (table 1).”
> “For the 101 attacks treated with deucrictibant and 100 treated with placebo, respectively, the attack primary location was reported as peripheral (58 [57%] of 101 vs 54 [54%] of 100), abdominal (38 [38%] of 101 vs 42 [42%] of 100), and non-severe laryngeal (two [2%] of 101 vs none), and severity as mild (18 [18%] of 101 vs 12 [12%] of 100), moderate (60 [59%] of 101 vs 47 [47%] of 100), and severe or very severe (17 [17%] of 101 vs 29 [29%] of 100) at pre-treatment (appendix p 25).”
> “These distributions of attacks were consistent with the primary efficacy analysis set for both groups (appendix p 25).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### Primary endpoint: time to onset of symptom relief, primary efficacy analysis set of 88 participants with paired attacks

> “Onset of symptom relief, the primary endpoint, was met significantly faster with deucrictibant compared with placebo (figure 2A; table 2), with a median time of 1·28 h (95% CI 1·05 to 1·52; p<0·0001) versus over 12 h (5·82 to >12), respectively.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.3-2"></a>

###### Primary and secondary endpoints by PGI-C and PGI-S, primary efficacy analysis set of 88 participants with paired attacks

> “Primary and secondary efficacy endpoints in the primary efficacy analysis set”
> “n refers to the number of randomly allocated participants who had two attacks treated with study drug following the 2 × 2 crossover design. N' refers to the number of participants with post-treatment data within the specified timeframe.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

| Endpoint and statistic | Deucrictibant N' | Deucrictibant result | Placebo N' | Placebo result | p value |
| --- | --- | --- | --- | --- | --- |
| Primary: time to onset of symptom relief (PGI-C), median time (95% CI), h | “83/88” | “1·28 (1·05 to 1·52)” | “87/88” | “>12 (5·82 to >12)” | “<0·0001” |
| Attacks meeting onset of symptom relief at 4 hours (PGI-C), n (%) | “83/88” | “69/83 (83%)” | “87/88” | “24/87 (28%)” | “<0·0001” |
| Time to substantial symptom relief (PGI-C), median time (95% CI), h | “83/88” | “2·85 (2·08 to 3·35)” | “87/88” | “>12 (10·30 to >12)” | “<0·0001” |
| Time to reduction in attack severity (PGI-S), median time (95% CI), h | “83/88” | “2·41 (1·70 to 2·98)” | “84/88” | “>12 (12·34 to >12)” | “<0·0001” |
| Time to complete symptom resolution (PGI-S), median time (95% CI), h | “83/88” | “11·95 (8·61 to 21·79)” | “87/88” | “>48 (>48 to >48)” | “<0·0001” |
| Time to end of progression (PGI-C), median time (95% CI), min | “83/88” | “17·47 (16·27 to 19·17)” | “87/88” | “228·67 (61·82 to 599·60)” | “<0·0001” |
| Complete symptom resolution with one dose at 24 hours (PGI-S), n (%) | “83/88” | “50/83 (60%)” | “87/88” | “13/88 (15%)” | “<0·0001” |

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.3-3"></a>

###### Secondary endpoints by PGI-C and PGI-S: median times, primary efficacy analysis set

> “Endpoints of time to substantial symptom relief, reduction in attack severity, complete symptom resolution, and end of progression, as assessed by PGI-C or PGI-S, were also reached faster for deucrictibant-treated attacks than for placebo-treated attacks (p<0·0001 for all endpoints).”
> “Median times to each secondary endpoint for deucrictibant and placebo, respectively, were 2·85 h (95% CI 2·08 to 3·35) and more than 12 h (10·30 to >12) to substantial symptom relief, 2·41 h (1·70 to 2·98) and more than 12 h (12·34 to >12) to reduction in attack severity, 11·95 h (8·61 to 21·79) and more than 48 h (>48 to >48) to complete symptom resolution, and 17·47 min (16·27 to 19·17) and 228·67 min (61·82 to 599·60) to end of progression (figure 2B–E; table 2).”
> “The percentage of attacks meeting onset of symptom relief at 4 h post-treatment was 69 (83%) of 83 for deucrictibant and 24 (28%) of 87 for placebo (p<0·0001; table 2).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.3-4"></a>

###### Company summary of the primary and secondary results, efficacy analysis of 88 participants with paired attacks

> “The efficacy analysis included paired attacks (one participant contributed one deucrictibant-treated attack and one placebo-treated attack) from 88 participants.”
> “time to complete attack resolution as measured by a PGI-S rating of "none" (11.95 hours vs. over 48 hours)”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-3.1.1.8.3-5"></a>

###### Time to complete symptom resolution, placebo median: topline statement, December 2025, superseded in March 2026

> “Median time to complete symptom resolution by PGI-S "none": 11.95 hours versus >24 hours (p<0.0001)”

Source: [Pharvaris RAPIDe-3 topline press release (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000119312525305951/d69798dex991.htm)

<a id="topic-3.1.1.8.3-6"></a>

###### End of progression median stated at NDA acceptance, July 2026

> “the median time to onset of symptom relief was 1.28 hours, to End of Progression™ (EoP) was 17.48 minutes”

Source: [Pharvaris NDA acceptance press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-announces-fda-acceptance-new-drug-application)

<a id="topic-3.1.1.8.3-7"></a>

###### Secondary endpoints by AMRA, primary efficacy analysis set

> “Endpoints assessed using AMRA also showed faster times to substantial symptom relief, almost complete or complete symptom resolution, and end of progression with deucrictibant compared with placebo (all p<0·0001).”
> “Median times for deucrictibant and placebo-treated attacks, respectively, were 3·37 h (95% CI 2·56 to 4·95) and more than 12 h (>12 to >12) to substantial symptom relief, 6·94 h (4·70 to 13·44) and more than 24 h (>24 to >24) to almost complete or complete symptom resolution, and 25·25 min (17·82 to 30·25) and 272·09 min (147·57 to >720) to end of progression (appendix pp 19, 27).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.3-8"></a>

###### Attacks reaching each endpoint within its prespecified timeframe, primary efficacy analysis set

> “The primary endpoint and these secondary efficacy endpoints were met within the relevant prespecified timeframe by 82–93% for deucrictibant-treated attacks and 37–61% for placebo-treated attacks (appendix p 18).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.3-9"></a>

###### Single capsule and second capsule use, primary efficacy analysis set of 88 paired attacks

> “For the primary analysis of 88 paired attacks, 73 (83%) and 69 (78%) of 88 deucrictibant-treated attacks and 29 (33%) and 27 (31%) of 88 placebo-treated attacks were treated with a single capsule within 12 h and 24 h, respectively (appendix p 26).”
> “A second capsule was used for 15 (17%) and 19 (22%) of 88 deucrictibant-treated attacks and 59 (67%) and 61 (69%) of 88 placebo-treated attacks within 12 h and 24 h, respectively (appendix p 26).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.3-10"></a>

###### Rescue medication use, primary efficacy analysis set

> “Conventional on-demand therapy as rescue medication was used within 12 h for six (7%) of 88 deucrictibant-treated attacks and 32 (36%) of 88 placebo-treated attacks (figure 3), and within 24 h for eight (9%) of 88 deucrictibant-treated attacks and 39 (44%) of 88 placebo-treated attacks (p<0·0001; figure 3; table 2).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

| Endpoint | Deucrictibant (n=88) | Placebo (n=88) | p value |
| --- | --- | --- | --- |
| Attacks using conventional on-demand therapy as rescue medication within 24 h, n (%) | “8/88 (9%)” | “39/88 (44%)” | “<0·0001” |

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.3-11"></a>

###### Complete symptom resolution with a single capsule at 24 hours, primary efficacy analysis set

> “At 24 h, the percentage of deucrictibant-treated attacks reaching complete symptom resolution with a single capsule was approximately four times higher compared with placebo-treated attacks (p<0·0001; table 2).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.3-12"></a>

###### Sustained response and single-capsule use among responding attacks, primary efficacy analysis set of 88 participants

> “The primary efficacy analysis set included 88 participants who had one deucrictibant-treated attack and one placebo-treated attack, for a total of 176 attacks.”
> “Study outcomes: time to onset of sustained symptom relief, time to sustained substantial symptom relief, sustained reduction in attack severity, and sustained complete symptom resolution, where a sustained response was defined as achieving and maintaining the efficacy endpoint across all remaining timepoints within the assessment duration.”
> “More than 95% of deucrictibant-treated attacks maintained achievement of the predefined clinical endpoints throughout the respective assessment periods”
> “Seventy-five of the 77 (97.4%) deucrictibant-treated attacks that achieved EoP within 12 hours were treated with a single capsule.”

Source: [Anderson et al. (2026c)](https://ir.pharvaris.com/static-files/9d17729a-c3ad-4b4b-a355-40e360776318)

<a id="topic-3.1.1.8.3-13"></a>

###### Sensitivity and supplementary analyses, 113 participants with at least one treated attack

> “Prespecified sensitivity analyses of the primary and secondary endpoints in the 113 participants with at least one study drug-treated attack yielded results that were consistent with the primary analyses (appendix pp 27–31), as did supplementary analyses of the primary endpoint using the per-protocol analysis set and using the treatment policy strategy analysis approach (appendix p 32).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.3-14"></a>

###### Subgroups by age, HAE type, long-term prophylaxis, and attack location and severity, participants with at least one treated attack

> “Sensitivity and subgroup analyses employed an expanded analysis set including all participants who treated at least one attack with study drug”
> “Outcomes were consistent across subgroups defined by age, hereditary angioedema types, whether concomitant long-term prophylaxis was used or not, and attack location and severity (appendix p 20).”
> “Efficacy outcomes were consistent across all clinically relevant subgroups defined according to age, geographical locations, hereditary angioedema type, concomitant use of long-term prophylaxis, and attack severities and locations.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.3-15"></a>

###### HAE with normal C1 inhibitor: two participants with one deucrictibant-treated attack each

> “In the two participants with hereditary angioedema with normal C1 inhibitor who each had one deucrictibant-treated attack, the time to onset of symptom relief was 1·53 h and 0·84 h, respectively.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.3-16"></a>

###### Regional subgroups, North America and Europe or rest of world: all participants with treated attacks

> “Analysis sets: subgroup analysis included all participants with treated attacks.”
> “In total, RAPIDe-3 enrolled 134 participants. The North American and European/Rest of World subgroups included 38 and 96 participants, respectively.”
> “In this regional subgroup analysis of the pivotal RAPIDe-3 trial, deucrictibant immediate-release (IR) capsule, an orally administered bradykinin B2 receptor antagonist, provided faster onset of symptom relief, reduction in attack severity, and complete resolution in both the North America and Europe/Rest of World subgroups compared with placebo.”

Source: [Adatia et al. (2026)](https://ir.pharvaris.com/static-files/9ecee56b-8c9c-475e-8f67-04661081af79)

| Region and endpoint | Deucrictibant | Placebo |
| --- | --- | --- |
| North America: time to onset of symptom relief, median | “1.20 hours (95% CI: 0.84, 1.84)” | “6.55 hours (95% CI: 1.88, >12)” |
| Europe/Rest of World: time to onset of symptom relief, median | “1.28 hours (95% CI: 1.04, 1.41)” | “>12 hours (95% CI: 5.74, >12)” |
| North America: time to reduction in attack severity, median | “2.43 hours (95% CI: 1.03, 5.12)” | “>12 hours (95% CI: 2.65, >12)” |
| Europe/Rest of World: time to reduction in attack severity, median | “2.53 hours (95% CI: 1.70, 2.98)” | “>12 hours (95% CI: 12.10, >12)” |
| North America: time to complete symptom resolution, median | “11.61 hours (95% CI: 2.94, 26.14)” | “>48 hours (95% CI: 17.21, >48)” |
| Europe/Rest of World: time to complete symptom resolution, median | “12.04 hours (95% CI: 8.64, 21.79)” | “>48 hours (95% CI: >48, >48)” |
| North America: onset of symptom relief at 4 hours | “77.8% (n=14/18)” | “46.2% (n=12/26)” |
| Europe/Rest of World: onset of symptom relief at 4 hours | “84.6% (n=66/78)” | “26.4% (n=19/72)” |

Source: [Adatia et al. (2026)](https://ir.pharvaris.com/static-files/9ecee56b-8c9c-475e-8f67-04661081af79)

<a id="topic-3.1.1.8.3-17"></a>

###### Pharmacokinetics in adolescents: ten participants in a non-attack state

> “Pharmacokinetic analyses were performed on samples from ten adolescent participants in non-attack state.”
> “Following a single capsule of deucrictibant, mean plasma levels reached the concentration estimated to provide 85% maximal response (EC85) of 13·8 ng/mL within 15 min and were maintained through to at least the last measured time point of 8 h.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.1.8.4-1"></a>

###### Health-related quality of life as exploratory endpoints

> “The primary and all secondary endpoints are reported here; health-related quality of life outcomes were assessed as exploratory endpoints and are planned to be published separately.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.4-2"></a>

###### In-trial qualitative interviews: design and sample of 91 participants

> “The trial included 60-minute, semi-structured, blinded, qualitative interviews (up to two) capturing participants’ descriptions of living with HAE, their attacks and associated symptoms, physical and emotional impacts of HAE, and fatigue/tiredness.”
> “A total of 141 interviews post attack (deucrictibant-treated, n=70; placebo-treated, n=71) were conducted with 91 of the 134 RAPIDe-3 participants across 19 countries.”
> “Of these, 50 participants across 16 countries completed the interviews for both attacks treated according to the crossover sequence; the remaining 41 participants completed an interview for a single attack during the study.”

Source: [Grumach et al. (2026)](https://ir.pharvaris.com/static-files/4dee9ac5-c7f0-489f-8d8a-197fc1d5da1a)

<a id="topic-3.1.1.8.4-3"></a>

###### In-trial qualitative interviews: attack-related impacts on health-related quality of life

> “Overall, participants reported experiencing eight negative HRQoL impacts with HAE attacks during the study, prior to the treatment with the study drug, in 113 interviews; the most frequently reported were fatigue (n=63/113 [55.8%]), emotional wellbeing (n=57/113 [50.4%]), and ADL (n=55/113 [48.7%])”
> “Despite using effective and well-tolerated HAE treatments in the past, 16/35 (45.7%) participants reported that deucrictibant-treated attacks had a lower negative impact on day-to-day life compared with prior attacks treated with other HAE treatments (Figure 5).”

Source: [Grumach et al. (2026)](https://ir.pharvaris.com/static-files/4dee9ac5-c7f0-489f-8d8a-197fc1d5da1a)

<a id="topic-3.1.1.8.4-4"></a>

###### In-trial qualitative interviews: on-demand treatments used before enrollment

> “All participants were asked about previous on-demand treatments used to treat HAE attacks before participating in RAPIDe-3: n=66/91 (72.5%) had used icatibant, n=41/91 (45.1%) human C1 inhibitor (C1INH), and n=7/91 (7.7%) recombinant C1INH.”
> “When participants (n=71) were asked to choose the most important aspect of their daily life they would have wanted to see improved with HAE treatment, 15/71 (21.1%) identified activities of daily living (ADL) and 14/71 (19.7%) said work/school (Figure 3).”

Source: [Grumach et al. (2026)](https://ir.pharvaris.com/static-files/4dee9ac5-c7f0-489f-8d8a-197fc1d5da1a)

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### Treatment-emergent adverse events, safety analysis set

> “Summary of treatment-emergent adverse events in the safety analysis set”
> “N refers to the total number of participants with at least one dose of study drug.”
> “Adolescent participants only.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

| Event category | Non-attack deucrictibant (n=10): participants, n (%) | Non-attack: events, n | Treated attack deucrictibant (n=100): participants, n (%) | Deucrictibant: events, n | Treated attack placebo (n=101): participants, n (%) | Placebo: events, n |
| --- | --- | --- | --- | --- | --- | --- |
| Any treatment-emergent adverse event | “3 (30%)” | “4” | “24 (24%)” | “40” | “17 (17%)” | “22” |
| Any treatment-emergent adverse event related to study drug | “0” | “0” | “5 (5%)” | “6” | “1 (1%)” | “1” |
| Any serious treatment-emergent adverse event | “0” | “0” | “1 (1%)” | “1” | “1 (1%)” | “1” |
| Any serious treatment-emergent adverse event related to study drug | “0” | “0” | “0” | “0” | “0” | “0” |
| Any severe treatment-emergent adverse event | “0” | “0” | “1 (1%)” | “2” | “1 (1%)” | “3” |
| Any severe treatment-emergent adverse event related to study drug | “0” | “0” | “0” | “0” | “0” | “0” |
| Any treatment-emergent adverse event within 3 days post-treatment | “0” | “0” | “15 (15%)” | “17” | “2 (2%)” | “3” |
| Treatment-emergent adverse event within 3 days related to study drug | “0” | “0” | “5 (5%)” | “6” | “1 (1%)” | “1” |
| Any serious treatment-emergent adverse event within 3 days post-treatment | “0” | “0” | “0” | “0” | “0” | “0” |
| Any severe treatment-emergent adverse event within 3 days post-treatment | “0” | “0” | “0” | “0” | “0” | “0” |
| Treatment-emergent adverse event leading to trial or study drug discontinuation | “0” | “0” | “0” | “0” | “0” | “0” |
| Treatment-emergent adverse event leading to death | “0” | “0” | “0” | “0” | “0” | “0” |
| Fatigue within 3 days post-treatment | “0” | “0” | “2 (2%)” | “2” | “0” | “0” |

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.5-2"></a>

###### Overall and 3-day adverse event rates, safety analysis set

> “Overall, 24 (24%) of 100 and 17 (17%) of 101 participants receiving deucrictibant and placebo, respectively, reported treatment-emergent adverse events (table 3).”
> “Treatment-emergent adverse events within 3 days post-treatment were reported by 15 (15%) and two (2%) participants receiving deucrictibant and placebo, respectively.”
> “In both groups, all events within 3 days were mild or moderate in severity.”
> “No treatment-emergent adverse events required emergency unmasking.”
> “A single event of fatigue occurred in two participants in the deucrictibant group within 3 days after treatment, one of which was deemed unrelated to treatment.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.5-3"></a>

###### Treatment-related adverse events

> “Six events in five participants in the deucrictibant group were reported as related to treatment as deemed by the investigators, all of which were observed once and resolved within 24 h spontaneously or with standard management (table 3).”
> “One event each of dyspepsia, fatigue, lethargy, brain fog, headache, and somnolence in deucrictibant-treated patients, and one event of pruritus in placebo-treated patients.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.5-4"></a>

###### Serious and severe adverse events

> “One participant who treated the first and only attack with placebo had a serious event of spontaneous miscarriage, reported 45 days post-treatment, and three additional severe events: endometrial hyperplasia, endometrial cancer, and bladder transitional cell carcinoma.”
> “One participant reported a serious event of laryngeal hereditary angioedema attack that occurred 132 days following deucrictibant treatment and required admission to hospital.”
> “The same participant reported two severe events of back pain and sacral pain 68 days following treatment with deucrictibant.”
> “None of the serious or severe events were considered related to study drug.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.5-5"></a>

###### Maximum severity grade of treatment-emergent adverse events, safety analysis set

| Participants with ≥1 TEAE by maximum grade | Placebo (N=101) | Deucrictibant (N=100) |
| --- | --- | --- |
| Any TEAEs | “17 (16.8)” | “24 (24.0)” |
| Maximum Grade 1 (Mild) | “10 (9.9)” | “13 (13.0)” |
| Maximum Grade 2 (Moderate) | “6 (5.9)” | “10 (10.0)” |
| Maximum Grade 3 (Severe) | “0” | “1 (1.0)” |
| Maximum Grade 4 (Life-threatening) | “1 (1.0)” | “0” |
| Maximum Grade 5 (Fatal) | “0” | “0” |

Source: [Pharvaris RAPIDe-3 topline data presentation (2025)](https://ir.pharvaris.com/static-files/30661839-e400-44eb-a1e9-9ad88f75d404)

<a id="topic-3.1.1.8.5-6"></a>

###### Laboratory, vital sign, and electrocardiogram findings and discontinuations

> “During the entire study, no treatment-emergent adverse events led to treatment discontinuation, or were associated with changes in clinical laboratory, vital signs, and electrocardiogram parameters.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-3.1.1.8.5-7"></a>

###### Capsule ingestion during abdominal and laryngeal attacks

> “No issues with capsule ingestion, such as difficulty swallowing, were reported, including for laryngeal attacks, and no reports of vomiting following study drug administration were reported in participants with abdominal symptoms.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

- The authors stated that “Limitations of this trial include the lack of attack stratification according to location and severity”, and that a larger proportion of severe attacks was therefore observed in the placebo group: severe or very severe attacks at pre-treatment were 17 (17%) of 101 deucrictibant-treated and 29 (29%) of 100 placebo-treated attacks. Two non-severe laryngeal attacks were treated with deucrictibant and none with placebo.
- Severe laryngeal attacks were not included, because of the risks of random assignment to double-masked placebo, and adolescents were instructed to treat laryngeal attacks of any severity with conventional on-demand therapy.
- The sponsor ended the trial after the prespecified number of participants with paired attacks was reached and before all participants had treated two attacks. Of 134 enrolled participants, 113 treated at least one attack and 88 contributed paired attacks to the primary efficacy analysis. One participant randomized to the deucrictibant-placebo sequence was given placebo in error and treated no second attack.
- Each participant treated at most one attack with deucrictibant in the crossover, and safety comparisons were descriptive. Treatment-emergent adverse events within 3 days of study drug were considered temporally clinically relevant.
- Subgroups were small: ten (7%) enrolled participants were adolescents, five of them in the primary efficacy analysis set, and only two unpaired attacks were recorded in participants with hereditary angioedema with normal C1 inhibitor.
- Eligibility required experience effectively using conventional on-demand therapy and excluded people older than 75 years, people with abnormal hepatic function or eGFR <60 ml/min/1.73 m2, users of strong CYP3A4 inhibitors or inducers, people with prior gene therapy, and pregnant or breastfeeding women.
- Use of rescue or selected prohibited medication was counted as treatment failure, and missing data at the end of follow-up were handled by right censoring without imputation.
- Health-related quality of life outcomes were exploratory endpoints planned for separate publication.

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext); [Pharvaris RAPIDe-3 topline data presentation (2025)](https://ir.pharvaris.com/static-files/30661839-e400-44eb-a1e9-9ad88f75d404); [Anderson et al. (2026c)](https://ir.pharvaris.com/static-files/9d17729a-c3ad-4b4b-a355-40e360776318); [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

<a id="heading-3.1.2"></a>

#### 3.1.2 RAPIDe-1

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Study aim in the publication

> “We aimed to investigate the efficacy and safety of deucrictibant for the on-demand treatment of hereditary angioedema attacks.”
> “The RAPIDe-1 phase 2 trial aimed to investigate whether oral deucrictibant, self-administered for on-demand treatment of hereditary angioedema attacks, would reduce attack severity, and also investigated the safety, tolerability and pharmacokinetics of deucrictibant.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.1-2"></a>

###### Registry brief summary

> “This study evaluates the efficacy of orally administered deucrictibant for the acute treatment of attacks in patients with hereditary angioedema (HAE).”
> “The study will compare symptom relief (skin pain, skin swelling, abdominal pain) during HAE attacks and safety of each dose of deucrictibant with placebo.”

Source: [ClinicalTrials.gov NCT04618211](https://clinicaltrials.gov/study/NCT04618211)

<a id="topic-3.1.2.1-3"></a>

###### Primary objective: symptom relief within 4 hours

> “Primary objective: to evaluate angioedema symptom relief within 4 hours in acute attacks of patients with HAE-1/2”

Source: [Riedl et al. (2023a)](https://ir.pharvaris.com/static-files/b15c3784-03fe-4925-aada-1331942c144e)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Registry dates and number of locations

> “Study Start (Actual) 2021-02-03 Primary Completion (Actual) 2022-09-23 Study Completion (Actual) 2023-03-01”
> “This study has 36 locations”

Source: [ClinicalTrials.gov NCT04618211](https://clinicaltrials.gov/study/NCT04618211)

<a id="topic-3.1.2.2-2"></a>

###### Sites, regions, and screening and randomization dates in the publication

> “Patients were recruited from 38 sites, including university hospitals and accredited angioedema centres, in North America, Europe, and Israel (appendix pp 2–4).”
> “Between Feb 3, 2021, and June 23, 2022, 89 patients were screened, of whom 74 were randomly assigned between Feb 23, 2021, and July 26, 2022 (figure 1).”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.2-3"></a>

###### Countries and sites at topline, December 2022

> “December 8, 2022”
> “today announced positive top-line data from the RAPIDe-1 Phase 2 clinical study”
> “Seventy-four patients were enrolled across 13 countries and were randomized into one of three single dose levels of PHVS416 and placebo.”
> “Pharvaris had previously announced the achievement of target enrollment across 33 sites in Canada, Europe, Israel, the UK, and the U.S.”

Source: [Pharvaris RAPIDe-1 topline press release (2022)](https://www.sec.gov/Archives/edgar/data/1830487/000156459022039123/phvs-ex991_935.htm)

<a id="topic-3.1.2.2-4"></a>

###### Sites reported in a March 2023 presentation

> “17-19 March 2023”
> “74 HAE patients enrolled from ~30 Sites in Canada, Europe, Israel, UK, and US”

Source: [Riedl et al. (2023a)](https://ir.pharvaris.com/static-files/b15c3784-03fe-4925-aada-1331942c144e)

<a id="topic-3.1.2.2-5"></a>

###### Trial start and topline timing

> “We commenced RAPIDe-1 in February 2021 and reported positive topline Phase 2 data in December 2022.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-3.1.2.2-6"></a>

###### U.S. clinical hold in August 2022 and partial lift for RAPIDe-1

> “In August 2022, the U.S. Food & Drug Administration (FDA) placed clinical studies of PHA121 in the U.S., including RAPIDe-1, on hold.”
> “Subsequent to the clinical holds, the company continues to evaluate PHVS416 for the treatment of acute attacks for continuing participants enrolled outside the U.S.”

Source: [Pharvaris RAPIDe-1 topline press release (2022)](https://www.sec.gov/Archives/edgar/data/1830487/000156459022039123/phvs-ex991_935.htm)

> “In August 2022, the U.S. Food & Drug Administration (FDA) placed a hold on the clinical trials of PHA121 in the U.S. based on its review of nonclinical data. FDA has subsequently agreed to partially lift the clinical hold on RAPIDe-1 trial”
> “and allow 2 remaining U.S. participants in RAPIDe-1 to complete treatment of a final HAE attack per protocol.”

Source: [Riedl et al. (2023a)](https://ir.pharvaris.com/static-files/b15c3784-03fe-4925-aada-1331942c144e)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Two-part, randomized, double-blind, placebo-controlled, crossover, dose-ranging design

> “RAPIDe-1 was a double-blind, randomised, placebo-controlled, crossover, dose-ranging, 2-part phase 2 trial. Part 1 assessed the pharmacokinetics and safety of three doses of a deucrictibant immediate-release capsule (henceforth referred to as deucrictibant): 10 mg, 20 mg, and 30 mg. Part 2 assessed their efficacy and safety versus placebo in achieving hereditary angioedema attack symptom reduction and resolution.”
> “There were no protocol amendments affecting trial recruitment or conduct during the study.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.3-2"></a>

###### Randomization to dose cohorts and crossover treatment sequences

> “Participants were randomly assigned (1:1:1) to one of three groups receiving deucrictibant (10 mg, 20 mg, or 30 mg) and further to one of three crossover treatment sequences (deucrictibant–deucrictibant–placebo, deucrictibant–placebo–deucrictibant, or placebo–deucrictibant–deucrictibant; appendix, p 21).”
> “Randomisation of treatment sequence assignment was done by an interactive response technology (IRT) system. Randomisation was stratified by whether the patients was willing to participate in full pharmacokinetic sampling, which was planned for approximately four patients from each dose cohort during an attack-free period in Part 1.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “From Part I to Part II, participants remained at their randomly assigned dose level.”

Source: [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211)

<a id="topic-3.1.2.3-3"></a>

###### Masking and identical capsules

> “Participants, investigators, site personnel, and the sponsor were masked to treatment assignment. Capsules of deucrictibant and placebo were identical and each single dose consisted of a combination of three capsules of deucrictibant or placebo in a wallet.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.3-4"></a>

###### Registry design details

> “Allocation : Randomized”
> “Interventional Model : Crossover Assignment”
> “Masking : Quadruple”

Source: [ClinicalTrials.gov NCT04618211](https://clinicaltrials.gov/study/NCT04618211)

<a id="topic-3.1.2.3-5"></a>

###### Investigator confirmation of each attack by remote consultation

> “Qualification of attacks for treatment with study drug had to be confirmed the Investigator or designee before administration of study drug via a remote consultation.”

Source: [Maurer et al. (2023a)](https://ir.pharvaris.com/static-files/351671e4-35b8-4bc3-a50d-ef96e17059ab)

<a id="topic-3.1.2.3-6"></a>

###### Safety visits, end-of-trial visit, and electronic attack diary

> “For qualifying attacks, patients recorded attack information via an electronic data capture device from attack onset to study drug administration and up to 48 h thereafter.”
> “Safety visits occurred up to and including 5 days from each treated attack, and an end-of-trial visit occurred 10 (± 5) days after the last attack or at trial withdrawal.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.3-7"></a>

###### Rollover to CHAPTER-1 or RAPIDe-2 after the trial

> “Following treatment of participation in RAPIDe-1, participants were eligible to either join the Phase 2 randomized clinical trial of deucrictibant for the prevention of HAE attacks (CHAPTER-1) or roll over to the long-term extension on-demand study (RAPIDe-2).”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Inclusion criteria in the publication: age, HAE type, and attack frequency

> “Adults aged 18–75 years with hereditary angioedema type 1 or 2, who had experienced two or more attacks within the past 2 months or three or more attacks within the past 4 months before screening were eligible for inclusion.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.4-2"></a>

###### Long-term prophylaxis exclusion and washout periods

> “Patients receiving long-term prophylactic therapy for hereditary angioedema at screening were not eligible. Patients who had previously discontinued long-term prophylaxis because of intolerance or lack of efficacy could enter the study provided that they had not been exposed to a C1 inhibitor, berotralstat, attenuated androgens, or anti-fibrinolytics at least 2 weeks before screening, and to lanadelumab 12 weeks before screening.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “Use of HAE therapies prior to enrolment: C1-inhibitor (C1-INH) for acute use or short-term prophylaxis (7 days); C1-INH for prophylaxis, oral kallikrein inhibitors, attenuated androgens, anti-fibrinolytics (2 weeks); monoclonal antibodies for HAE therapy (12 weeks);”

Source: [Maurer et al. (2023a)](https://ir.pharvaris.com/static-files/351671e4-35b8-4bc3-a50d-ef96e17059ab)

<a id="topic-3.1.2.4-3"></a>

###### Hepatic and renal function, CYP3A4 inhibitors or inducers, and pregnancy

> “Patients were excluded in cases of abnormal hepatic or renal function, or if they were receiving moderate or potent CYP3A4 inhibitors or inducers. As reproductive and developmental toxicity studies were not available for deucrictibant and potential effects of deucrictibant on the fetus were unknown, pregnant and breastfeeding women were not eligible.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.4-4"></a>

###### Registry key inclusion and exclusion criteria

> “Documented history of HAE attacks: at least three in the last 4 months, or at least two in the last 2 months prior to screening”
> “Reliable access and experience to use standard of care acute attack medications”
> “Clinically significant abnormal electrocardiogram”
> “Positive serology for HIV or active infection with hepatitis B virus or hepatitis C virus”
> “History of alcohol or drug abuse within defined period, or current evidence of substance dependence or abuse”
> “18 Years to 75 Years”

Source: [ClinicalTrials.gov NCT04618211](https://clinicaltrials.gov/study/NCT04618211)

<a id="topic-3.1.2.4-5"></a>

###### Attack-level criteria: qualifying and excluded attacks

> “Attacks with any symptoms involving the internal head or neck, including laryngeal attacks, or presenting with vomiting, did not qualify for study drug treatment and patients were instructed to immediately treat with standard on-demand medication. Attacks involving the face or neck with cutaneous manifestations were eligible for study drug treatment. Attacks occurring less than 5 days after a previously treated attack were also excluded.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Part 1 single dose in the attack-free state and Part 2 home self-administration

> “During Part 1, patients in a non-attack state received the assigned single dose of deucrictibant at the trial site to assess safety. Selected patients underwent plasma sampling before and after the single dose for pharmacokinetic assessments. In Part 2, patients were instructed to self-administer deucrictibant at home in the assigned treatment sequence to treat three investigator-confirmed qualifying attacks within 3 h after at least one symptom (skin pain, skin swelling, or abdominal pain) reached a visual analog scale (VAS) individual score of at least 30 out of 100 and within 6 h from symptom onset.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.5-2"></a>

###### Doses and crossover sequences per dose cohort

> “In Part I, participants in a quiescent state received a single dose of PHA-022121 at the assigned dose (10, 20, or 30 mg) to assess PK and safety. In Part II, participants received 2 single doses of PHA-022121 (10, 20, or 30 mg) and one single dose of placebo to assess efficacy and safety. Each participant administered their randomly assigned dose (either 10, 20, or 30 mg) for each of the 3 qualifying HAE attacks according to 1 of the 3 randomly assigned treatment sequences (crossover design).”

Source: [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211)

<a id="topic-3.1.2.5-3"></a>

###### Registry interventions: soft capsules and matching placebo

> “deucrictibant soft capsules for oral use”
> “PHA-022121 PHA121 PHVS416”
> “Matching placebo capsules for oral use”

Source: [ClinicalTrials.gov NCT04618211](https://clinicaltrials.gov/study/NCT04618211)

<a id="topic-3.1.2.5-4"></a>

###### Formulation: PHVS416 softgel capsule

> “PHVS416 is an investigational softgel capsule formulation containing PHA121, a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor.”

Source: [Pharvaris RAPIDe-1 topline press release (2022)](https://www.sec.gov/Archives/edgar/data/1830487/000156459022039123/phvs-ex991_935.htm)

<a id="topic-3.1.2.5-5"></a>

###### Rescue medication permitted from 4 hours after study drug

> “At 4 h or more after study drug administration, conventional on-demand therapy as rescue medication was allowed in case of insufficient symptom relief.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.5-6"></a>

###### Dose selection based on the bradykinin challenge and EC85

> “EC85 levels were established as threshold for therapeutic exposure using bradykinin challenge, a human in vivo surrogate-marker study in healthy volunteers”

Source: [Maurer et al. (2023a)](https://ir.pharvaris.com/static-files/351671e4-35b8-4bc3-a50d-ef96e17059ab)

> “From the bradykinin challenge model, we were able to predict the efficacious dose range and the duration of effect of a single oral dose of deucrictibant; the topline data from our Phase 2 RAPIDe-1 trial treating HAE attacks were consistent with the predictions of the bradykinin challenge in both onset of symptom relief and duration of effect (use of rescue medication).”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Change in the 3-Symptom Composite Visual Analogue Scale Score as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Primary endpoint: definition and assessment schedule in the publication

> “The primary efficacy endpoint was change in the patient-reported composite VAS score (VAS-3)”
> “The VAS-3 was calculated as the mean of three individual VAS scores assessing the three major hereditary angioedema symptoms: skin swelling, skin pain, and abdominal pain. Each symptom was rated separately on a 0–100 scale, where 0 indicated no swelling (for skin swelling) or no pain (for skin and abdominal pain), and 100 indicated extreme swelling or extreme pain, respectively. Scores were recorded before treatment, every 30 min (± 10) up to 4 h, and at 5 h (± 0·5), 6 h (± 0·5), 8 h (± 1), 24 h (± 4), and 48 h (± 6) post-treatment thereafter.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.6.1-2"></a>

###### Primary endpoint: registry definition

> “The primary endpoint of the study was the change of the VAS-3 (3-symptom composite visual analogue scale) score from pre-treatment to 4 hours post-treatment. The VAS-3 was calculated as the mean of the VAS scores of the 3 major HAE symptoms: skin swelling, skin pain, and abdominal pain. The VAS scores of the 3 major HAE symptoms (skin swelling, skin pain, and abdominal pain) could range between 0 (No swelling/No pain) and 100 (Extreme swelling/Excruciating pain)”

Source: [ClinicalTrials.gov NCT04618211](https://clinicaltrials.gov/study/NCT04618211)

<a id="topic-3.1.2.6.1-3"></a>

###### Electronic, numerically assisted capture of the VAS-3

> “The primary endpoint of the study (Table 1) is the change of a three-symptom composite (skin pain, skin swelling, abdominal pain) visual analogue scale (VAS-3) score from pre-treatment to four hours post-treatment, as captured electronically using numerically assisted input.”

Source: [Pharvaris RAPIDe-1 topline press release (2022)](https://www.sec.gov/Archives/edgar/data/1830487/000156459022039123/phvs-ex991_935.htm)

<a id="topic-3.1.2.6.1-4"></a>

###### Authors' rationale: 4-hour timepoint and scales used in earlier on-demand trials

> “Change was evaluated at 4 h as in other previous on-demand trials in hereditary angioedema.”
> “The scales and outcomes used in this trial were validated for hereditary angioedema and previously used in randomised controlled trials for on-demand treatment.”
> “In a trial of subcutaneous icatibant,”
> “the difference in mean VAS-3 score 4 h after treatment with icatibant and placebo was similar to that between deucrictibant and placebo in RAPIDe-1.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.6.1-5"></a>

###### Sponsor rationale: VAS in icatibant and recombinant C1 esterase inhibitor approvals and the FDA outcome assessment compendium

> “VAS-3 is a measure of HAE attack severity based on electronically-captured numerically-assisted visual scale”
> “Used in approval of two most recently approved on-demand therapies”
> “Icatibant and recombinant C1 esterase inhibitor”
> “VAS, MSCS, TOS are only endpoints listed for attacks in FDA compendium of clinical outcome assessments (2021) as listed by Division of Pulmonology, Allergy and Critical Care”

Source: [Riedl et al. (2023a)](https://ir.pharvaris.com/static-files/b15c3784-03fe-4925-aada-1331942c144e)

<a id="topic-3.1.2.6.1-6"></a>

###### Three-symptom VAS in the icatibant FAST-1 and FAST-2 trials

> “Patients presenting with cutaneous or abdominal attacks were asked to evaluate the severity of three specific symptoms (cutaneous swelling, cutaneous pain, and abdominal pain) on a visual-analogue scale.”
> “A composite score on the visual-analogue scale was calculated by taking the average of the three scores for the main symptoms”
> “and defining symptom relief as a 50% reduction from the baseline score.”
> “On the basis of the composite scores, the median time to symptom relief was 2.5 hours with icatibant versus 7.0 hours with placebo (P = 0.02) in FAST-1 and 2.0 hours with icatibant versus 15.0 hours with tranexamic acid (P<0.001) in FAST-2”

Source: [Cicardi et al. (2010a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4662377/)

<a id="topic-3.1.2.6.1-7"></a>

###### Content validity of HAE VAS instruments

> “It demonstrated the content validity of the four anatomical location HAE VAS instruments and their suitability for use in clinical trials of recombinant human C1INH (rhC1INH) treatment for ascertaining trial participants' assessments of the severity of acute angioedema symptoms.”

Source: [McMillan et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22462765/)

<a id="topic-3.1.2.6.1-8"></a>

###### VAS-3 in earlier on-demand trials and its adaptation to electronic AMRA instruments

> “The visual analog scale 3-symptom (VAS-3) and 5-symptom (VAS-5) are PROs that have also been used in earlier clinical trials of ODTs for HAE to derive key endpoints for clinical outcomes, such as a ≥30% or ≥50% reduction in symptom severity”
> “However, VAS-3 and VAS-5 were adapted into electronic assessments and renamed AMRA-3 (used for non-upper-airway attacks) and AMRA-5 (used for upper-airway attacks, including laryngeal attacks) and, therefore, require content validation and assessment of their psychometric properties in the HAE population”

Source: [Mendivil et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12953491/)

<a id="topic-3.1.2.6.1-9"></a>

###### Key secondary endpoints: time-to-event VAS-3 outcomes, MSCS, and TOS

> “Key secondary efficacy endpoints were time to symptom relief onset (≥30% reduction in VAS-3 score from pre-treatment), time to 50% or greater reduction in VAS-3 score, and time to almost complete or complete symptom resolution (all individual VAS scores ≤10 for two consecutive assessments), along with change in mean symptom complex severity (MSCS) score from pre-treatment to 4 h post-treatment, and treatment outcome score (TOS) at 4 h post-treatment.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.6.1-10"></a>

###### Key secondary endpoint: registry definition of almost complete or complete symptom relief

> “Almost complete symptom relief is defined as all 3 individual VAS scores of the VAS-3 having a value < 10. Complete symptom relief is defined as all 3 individual VAS scores are of the VAS-3 having a value of 0.”

Source: [ClinicalTrials.gov NCT04618211](https://clinicaltrials.gov/study/NCT04618211)

<a id="topic-3.1.2.6.1-11"></a>

###### Key secondary endpoints: MSCS and TOS instruments

> “Mean Symptom Complex Severity (MSCS) score and Treatment Outcome Score (TOS) are validated composite scores based on patient-reported symptoms of attacks at the affected body sites, included in ecallantide clinical trials”
> “MSCS is a point-in-time measure of symptom severity”
> “Patient-rated severity of each affected symptom on a categorical scale (0 = normal, 1 = mild, 2 = moderate, 3 = severe)”
> “TOS is a measure of symptom response to treatment”
> “Patient assessment of response for each affected body site on categorical scale (significant improvement [100], improvement [50], same [0], worsening [-50], significant worsening [-100])”

Source: [Riedl et al. (2023b)](https://ir.pharvaris.com/static-files/1d0c218c-12ee-4a4e-93bc-b9c939dac963)

<a id="topic-3.1.2.6.1-12"></a>

###### Key secondary endpoints: validation and minimally important differences of TOS and MSCS

> “Anchor- and distribution-based analyses suggested that conservative estimates for MID are 30 points for TOS and -0.30 points for 4-h change in MSCS score.”
> “The psychometric tests performed here provide evidence of the reliability and validity of the TOS and MSCS for evaluating symptom severity and change in HAE patients.”

Source: [Vernon et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19597964/)

<a id="topic-3.1.2.6.1-13"></a>

###### Other secondary endpoints: rescue medication use and lower-ranked endpoints including TSQM

> “Rescue medication use was an additional secondary outcome and was assessed as the proportion of study drug-treated attacks with conventional therapy within 12 h, 24 h, and 48 h post-treatment and time to first rescue medication use. Time to 30% or greater and 50% or greater reduction in VAS for the primary symptom, change in the VAS score for individual symptoms from pre-treatment to 4 h, change in MSCS score from pre-treatment to 24 h post-treatment, TOS at 24 h post-treatment, and Treatment Satisfaction Questionnaire for Medication (TSQM) score, were other lower-ranked secondary endpoints and will be reported elsewhere.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.6.1-14"></a>

###### Other secondary endpoint: TSQM registry definition

> “The 11-item TSQM (version II) evaluated participant treatment satisfaction with the medication for the following scales: effectiveness, side effects, convenience, and overall satisfaction Scale scores were transformed into scores ranging from 0 to 100 and could be used to calculate a total composite score, a higher score indicating greater satisfaction.”

Source: [ClinicalTrials.gov NCT04618211](https://clinicaltrials.gov/study/NCT04618211)

<a id="topic-3.1.2.6.1-15"></a>

###### Safety endpoints

> “Safety endpoints were adverse events occurring within 5 days of treatment. Adverse event reporting information collected included time of onset, severity, relationship to study drug, action taken, outcome, and date of resolution. Additionally, pharmacokinetics was investigated for all doses.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.6.1-16"></a>

###### Post hoc endpoint: time to end of progression

> “A recent consensus study established EoP as a key core outcome score that should be measured and reported in all clinical trials for on-demand treatment of HAE”
> “A post-hoc analysis was conducted to assess time to EoP of HAE attack manifestations in the RAPIDe-1 trial.”
> “Time to EoP was defined as the earliest post-treatment timepoint with the highest 3-symptom composite (skin pain, skin swelling, abdominal pain) visual analogue scale (VAS-3) score with no use of rescue medication.”

Source: [Riedl et al. (2023c)](https://ir.pharvaris.com/static-files/0bae214b-7ff8-49ec-8340-1bb60a5935b9)

Additional sources: [Lumry et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/22123383/)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Sample size and power assumptions

> “Based on previous trials”
> “and assuming a treatment effect difference of 10 points (with an SD of 11) in VAS-3 score change from pre-treatment to 4 h post-treatment between deucrictibant (20 mg or 30 mg) and placebo, 72 randomly assigned patients were expected to provide 90% power to test the primary endpoint at a significance level of 2·5% for a two-sided test, accounting for attrition in evaluable attacks and possible rescue medication use.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.7.1-2"></a>

###### Registry enrollment and participants randomized per dose cohort

> “Enrollment (Actual) 74”

Source: [ClinicalTrials.gov NCT04618211](https://clinicaltrials.gov/study/NCT04618211)

> “A total of 89 patients were screened, of which 74 patients were enrolled and randomized to the 3 PHA-022121 cohorts as follows: 25 participants to the 30 mg cohort, 25 participants to the 20 mg cohort, and 24 participants to the 10 mg cohort.”

Source: [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211)

<a id="topic-3.1.2.7.1-3"></a>

###### Participants and attacks in the primary efficacy analysis

> “The primary efficacy analysis included 147 attacks in 62 patients, of whom 42 (68%) were female and 60 (97%) were White.”
> “Of the 147 study drug-treated attacks, 37 (25%) were in 21 patients treated with deucrictibant 10 mg, 28 (19%) were in 16 patients treated with deucrictibant 20 mg, 31 (21%) were in 20 patients treated with deucrictibant 30 mg, and 51 (35%) were in 51 patients treated with placebo (table 2).”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.7.1-4"></a>

###### Participants and attacks in the safety analysis set

> “In Part 1, eight (11%) of 72 patients in the safety analysis set reported treatment-emergent adverse events within 5 days post-treatment”
> “In Part 2, the safety analysis set included 156 attacks treated with deucrictibant 10 mg, 20 mg, 30 mg, or placebo.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “156 attacks from 73 patients were included in the Safety Analysis Set”
> “147 attacks from 62 patients were included in the mITT Analysis Set for efficacy”

Source: [Riedl et al. (2023a)](https://ir.pharvaris.com/static-files/b15c3784-03fe-4925-aada-1331942c144e)

<a id="topic-3.1.2.7.1-5"></a>

###### Attacks in the final analysis and participants with pharmacokinetic sampling

> “The final analysis included 165 attacks, with nine additional attacks that occurred after data cutoff for the primary analysis.”
> “Pharmacokinetics were assessed in samples collected from 12 patients during Part 1.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Full analysis set

> “The primary analysis (full analysis set) comprised all patients enrolled and randomly assigned in the study.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “The FAS was defined as all participants enrolled and randomized in the study. Participants were analyzed based on the intention-to-treat principle, i.e., according to their randomized treatment assignment regardless of actual treatment taken.”

Source: [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211)

<a id="topic-3.1.2.7.2-2"></a>

###### Modified intention-to-treat and per-protocol analysis sets

> “The primary endpoint and key secondary endpoints were analysed in the modified intention-to-treat (mITT) analysis set (defined as patients with ≥1 study drug-treated attack and VAS-3 data at pre-treatment and ≥1 post-treatment timepoints) and also repeated with the per-protocol analysis set (defined as a subset of the mITT analysis set, comprising all patients who had at least one attack satisfying mITT analysis set criteria, and who also had no major protocol deviations or other non-compliance that could affect the key efficacy assessment) as a prespecified supplementary analysis.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.7.2-3"></a>

###### Safety and pharmacokinetic analysis sets

> “The safety analysis set comprised all patients who received at least one dose of study drug, and analyses were summarised by dose. Pharmacokinetic analyses were conducted for patients who received at least one dose of study drug and had at least one measurable concentration of deucrictibant in Part 1.”
> “In part 1, adverse event data are provided as frequencies and percentages of patients. In part 2, adverse event data are provided as frequencies and percentages of attacks with adverse events as well as frequencies and percentages of patients.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.7.2-4"></a>

###### Primary analysis before all participants had three attacks, and descriptive final analysis

> “The primary analysis, planned as a formal analysis in the trial protocol to assess the objectives of this study, was done before all enrolled patients had three qualifying attacks. A final analysis was subsequently conducted on data collected through to the end of the trial for descriptive purposes.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.7.2-5"></a>

###### Primary endpoint model: mixed model for repeated measures

> “A mixed model for repeated measures (MMRM) was used to estimate the least squares mean difference in VAS-3 score change from pre-treatment to 4 h post-treatment between each deucrictibant dose and placebo.”
> “The MMRM included treatment, time, treatment-by-time interaction, as well as attack as fixed effects, patient as a random effect, and attack specific pre-treatment VAS-3 value as a covariate. A heterogeneous Toeplitz covariance structure was assumed. VAS-3 results after the intake of rescue medication or prohibited medication were set to missing.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.7.2-6"></a>

###### Prespecified sensitivity analyses of the primary endpoint

> “For the primary endpoint, a prespecified sensitivity analysis was done with the missing not at random (MNAR) assumption. VAS-3 results after the intake of hereditary angioedema rescue medication or prohibited medications were set to missing and handled with control-based multiple imputation. Other prespecified sensitivity analyses, such as an analysis using only the first treated attack of each patient, and an analysis excluding data with inconsistent reporting between VAS and MSCS or TOS, were also done to assess the robustness of the primary conclusions.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.7.2-7"></a>

###### Multiplicity control for the 20 mg and 30 mg branches, and descriptive 10 mg analyses

> “Initially, the full α=0·05 was split equally (α=0·025) and allocated to two branches corresponding to the hypotheses for deucrictibant 20 mg versus placebo and deucrictibant 30 mg versus placebo. Within each branch, endpoints were tested sequentially: the primary endpoint first, followed by the key secondary endpoints in the prespecified hierarchical order.”
> “The 10 mg group was included to evaluate dose–response without multiplicity control procedures, and analyses were therefore descriptive.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “The statistical tests for the primary and all key secondary endpoints followed a pre-specified multiple comparison procedure to assess statistical significance for PHVS416 20 mg and 30 mg, supported by a nominal statistical analysis for PHVS416 10 mg.”

Source: [Pharvaris RAPIDe-1 topline press release (2022)](https://www.sec.gov/Archives/edgar/data/1830487/000156459022039123/phvs-ex991_935.htm)

<a id="topic-3.1.2.7.2-8"></a>

###### Time-to-event and rescue medication analyses

> “Time-to-event endpoints were summarised with the Kaplan–Meier method, and treatment effect was estimated by use of marginal Cox proportional hazards models with robust variance-covariance estimator to account for within-patient correlation. For attacks not achieving the outcome of interest at predefined timepoints, the time was censored at the last recorded assessment. For attacks with rescue medication or prohibited medication use, time was censored at the last assessment recorded before rescue medication or prohibited medication.”
> “For the evaluation of rescue medication use, odds ratios with 95% CIs and p values were estimated with a generalised estimating equation model with a logit link, adjusting for treatment, attack, and pre-treatment VAS-3 value, with an identity matrix specified as the working correlation structure.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.7.2-9"></a>

###### Registry caveat on Kaplan-Meier medians

> “the within participant correlation was not accounted for in the Kaplan-Meier estimation of median time and corresponding 95% confidence interval.”
> “Participant flow is reported according to randomized treatment cohort, efficacy”

Source: [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Screening, randomization, and follow-up in the primary analysis set

> “Between Feb 3, 2021, and June 23, 2022, 89 patients were screened, of whom 74 were randomly assigned between Feb 23, 2021, and July 26, 2022 (figure 1). For the primary analysis set, the median follow-up was 130·0 (IQR 92·5–212·5) days for deucrictibant 10 mg, 166·5 (80·0–275·0) days for deucrictibant 20 mg, and 172·0 (65·0–242·0) days for deucrictibant 30 mg. Similar numbers of patients across the groups completed Part 1, treated one, two, or three attacks in Part 2, and completed post-attack visits before the primary analysis cutoff (figure 1).”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.8.1-2"></a>

###### Registry participant flow by randomized dose cohort, Part I and Part II

| Milestone | Deucrictibant 10 mg cohort | Deucrictibant 20 mg cohort | Deucrictibant 30 mg cohort |
| --- | --- | --- | --- |
| Part I started | “24” | “25” | “25” |
| Part I completed | “24” | “24” | “25” |
| Part I withdrawal by subject | “0” | “1” | “0” |
| Part II started | “24” | “24” | “25” |
| Part II completed | “16” | “12” | “12” |
| Part II not completed | “8” | “12” | “13” |
| Part II withdrawal by subject | “2” | “3” | “5” |
| Part II not completed: “Participants Met Primary Analysis Criteria” | “6” | “9” | “8” |

Source: [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211)

> “Participant flow is reported according to randomized treatment cohort”

Source: [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211)

<a id="topic-3.1.2.8.1-3"></a>

###### Follow-up in the final analysis

> “The median follow-up was 130·0 days (IQR 92·5–249·0) for deucrictibant 10 mg, 190·5 days (94·0–384·5) for deucrictibant 20 mg, and 174·0 days (65·0–330·0) for deucrictibant 30 mg.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Demographics and HAE characteristics by dose cohort, full analysis set

| Characteristic | Deucrictibant 10 mg (n=24) | Deucrictibant 20 mg (n=25) | Deucrictibant 30 mg (n=25) |
| --- | --- | --- | --- |
| Age, years, median (IQR) | “44 (31–53)” | “45 (36–57)” | “39 (25–53)” |
| Female, n (%) | “17 (71%)” | “17 (68%)” | “15 (60%)” |
| White, n (%) | “22 (92%)” | “24 (96%)” | “25 (100%)” |
| HAE-C1INH type 1, n (%) | “19 (79%)” | “22 (88%)” | “24 (96%)” |
| HAE-C1INH type 2, n (%) | “5 (21%)” | “2 (8%)” | “1 (4%)” |
| Time since diagnosis, years, median (IQR) | “18 (10–26)” | “21 (13–37)” | “23 (10–37)” |
| More than 4 attacks in the 4 months before screening, n (%) | “20 (83%)” | “20 (80%)” | “20 (80%)” |
| Long-term prophylactic treatment history, n (%) | “3 (13%)” | “5 (20%)” | “5 (20%)” |

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “Demographics and baseline clinical characteristics of the full analysis set”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.8.2-2"></a>

###### Attack frequency and prior HAE medication, full analysis set

> “Demographics and baseline characteristics, including hereditary angioedema-related medical history, were balanced across groups and similar to those in another recent trial of on-demand treatment (table 1; appendix pp 7–8).”
> “Of 74 patients, 68 (92%) had experienced four or more attacks in the 4 months before screening. Previous use of hereditary angioedema medication (primarily icatibant and a C1 inhibitor) was reported for 70 (95%) of 74 patients; 13 (18%) patients reported previous long-term prophylaxis use.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.8.2-3"></a>

###### Registry baseline age and ethnicity, full analysis set

| Characteristic | Deucrictibant 10 mg | Deucrictibant 20 mg | Deucrictibant 30 mg | Total |
| --- | --- | --- | --- | --- |
| Participants | “24” | “25” | “25” | “74” |
| Age, years, mean (SD) | “42.9” (“14.15”) | “45.7” (“13.89”) | “41.4” (“15.38”) | “43.3” (“14.41”) |
| Aged 65 to 84 years | “2” | “1” | “2” | “5” |
| Hispanic or Latino | “3” | “2” | “0” | “5” |

Source: [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211)

> “Full Analysis Set (FAS): The FAS was defined as all participants enrolled and randomized in the study.”

Source: [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211)

<a id="topic-3.1.2.8.2-4"></a>

###### Sex and race, mITT analysis set of 62 participants

> “The mITT analysis set for the primary analysis comprised 62 patients, of whom 42 (68%) were female and 60 (97%) were White (appendix pp 7–8).”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.8.2-5"></a>

###### Pre-treatment VAS-3 scores of treated attacks, mITT analysis set

| Treatment of the attack | Attacks | Pre-treatment VAS-3, mean (SD) |
| --- | --- | --- |
| Deucrictibant 10 mg | “37” | “26·16 (11·67)” |
| Deucrictibant 20 mg | “28” | “25·46 (10·00)” |
| Deucrictibant 30 mg | “31” | “29·73 (13·53)” |
| Placebo | “51” | “27·76 (11·25)” |

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “Primary and secondary endpoints in the modified intention-to-treat analysis set”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “Median VAS-3 at pre-treatment ranged from 24.33 to 27.00 across different dose levels”

Source: [Riedl et al. (2023a)](https://ir.pharvaris.com/static-files/b15c3784-03fe-4925-aada-1331942c144e)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### Primary endpoint: change in VAS-3 at 4 hours, deucrictibant 10, 20, and 30 mg versus placebo, mITT analysis set of 147 attacks in 62 participants

| Measure | Deucrictibant 10 mg (n=21) | Deucrictibant 20 mg (n=16) | Deucrictibant 30 mg (n=20) | Placebo (n=51) |
| --- | --- | --- | --- | --- |
| Attacks with VAS-3 at 4 h | “33” | “27” | “30” | “43” |
| VAS-3 at 4 h, mean (SD) | “12·09 (14·47)” | “11·93 (9·97)” | “14·71 (10·51)” | “30·09 (18·20)” |
| LSM difference vs placebo (95% CI) | “−16·75 (−21·52 to −11·97)” | “−15·02 (−20·22 to −9·81)” | “−16·28 (−21·27 to −11·29)” | Not applicable |
| p value | Not reported | “<0·0001” | “<0·0001” | Not applicable |

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “Primary and secondary endpoints in the modified intention-to-treat analysis set”
> “The primary efficacy analysis included 147 attacks in 62 patients”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “Deucrictibant 20 mg and 30 mg significantly reduced the severity of attack symptoms, measured as a change in VAS-3 score at 4 h post-treatment versus placebo; the least squares mean difference was –15·02 (95% CI –20·22 to –9·81) for 20 mg and –16·28 (–21·27 to –11·29) for 30 mg (p<0·0001 for both; figure 2A; table 2). For the 10 mg treatment group, the least squares mean difference was –16·75 (95% CI –21·52 to –11·97).”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.8.3-2"></a>

###### Primary endpoint: registry least squares mean change and nominal p value for 10 mg, participants with evaluable data

| Group | Participants | LS mean change in VAS-3 (SE) | LS mean difference vs placebo (95% CI) | p value |
| --- | --- | --- | --- | --- |
| Deucrictibant 10 mg | “21” | “-14.83” (“1.833”) | “-16.75” (“-21.52” to “-11.97”) | “< 0.0001”, “Nominal p-value” |
| Deucrictibant 20 mg | “16” | “-13.10” (“2.111”) | “-15.02” (“-20.22” to “-9.81”) | “< 0.0001” |
| Deucrictibant 30 mg | “20” | “-14.37” (“1.975”) | “-16.28” (“-21.27” to “-11.29”) | “< 0.0001” |
| Placebo | “51” | “1.92” (“1.596”) | Not applicable | Not applicable |

Source: [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211)

> “Part I efficacy data not collected, consistent with and pre-specified in the study protocol. Includes all participants with evaluable data who completed the relevant assessment time point.”

Source: [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211)

<a id="topic-3.1.2.8.3-3"></a>

###### Primary endpoint: sensitivity analyses and VAS-3 course over time

> “Prespecified sensitivity and supplementary analyses yielded results consistent with those of the primary statistical analysis, supporting the robustness of the primary findings (appendix pp 9–10). At each timepoint from 1–24 h post-treatment, mean VAS-3 score decreased for deucrictibant-treated attacks, whereas it remained stable for placebo-treated attacks until declining at 4 h, primarily due to censoring at use of rescue medication (appendix p 22).”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.8.3-4"></a>

###### Primary endpoint: post hoc pooled deucrictibant doses versus placebo

> “Combined PHVS416 -16.08 (-19.87, -12.29)”
> “The Combined PHVS416 results are based on post-hoc analysis using a similar MMRM with all three active doses combined vs placebo.”

Source: [Riedl et al. (2023a)](https://ir.pharvaris.com/static-files/b15c3784-03fe-4925-aada-1331942c144e)

<a id="topic-3.1.2.8.3-5"></a>

###### Key secondary endpoints: multiplicity-controlled results for 20 mg and 30 mg

> “In the efficacy evaluation, following the planned multiplicity control procedure for testing the primary and key secondary endpoints, all the hypotheses in each branch (20 mg and 30 mg) were successfully rejected at the allocated α=0·025.”
> “Statistical significance was achieved in treatment effect compared to placebo for the primary endpoint and all key secondary endpoints for both 20 mg and 30 mg.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.8.3-6"></a>

###### Key secondary endpoints: time to symptom relief, 50% reduction, and resolution by VAS-3, deucrictibant 10, 20, and 30 mg versus placebo, mITT analysis set

| Endpoint and measure | Deucrictibant 10 mg (37 attacks) | Deucrictibant 20 mg (28 attacks) | Deucrictibant 30 mg (31 attacks) | Placebo (51 attacks) |
| --- | --- | --- | --- | --- |
| Onset of symptom relief (≥30% VAS-3 reduction), median h (95% CI) | “2·1 (1·5 to 2·9)” | “2·7 (1·9 to 3·5)” | “2·5 (1·9 to 3·8)” | “8·0 (7·6 to NE)” |
| Onset of symptom relief, hazard ratio (95% CI) | “3·81 (2·01 to 7·20)” | “3·08 (1·50 to 6·30)” | “3·61 (2·10 to 6·19)” | Not applicable |
| Onset of symptom relief, p value | Not reported | “0·0021” | “<0·0001” | Not applicable |
| ≥50% VAS-3 reduction, median h (95% CI) | “3·3 (2·4 to 3·9)” | “4·0 (2·9 to 6·0)” | “4·0 (3·3 to 5·8)” | “22·8 (20·0 to 24·1)” |
| ≥50% VAS-3 reduction, hazard ratio (95% CI) | “4·55 (2·41 to 8·59)” | “3·65 (1·80 to 7·38)” | “3·87 (2·26 to 6·63)” | Not applicable |
| ≥50% VAS-3 reduction, p value | Not reported | “0·0003” | “<0·0001” | Not applicable |
| Almost complete or complete symptom relief, median h (95% CI) | “5·8 (3·6 to 7·5)” | “20·0 (4·5 to 20·0)” | “20·0 (6·0 to 20·1)” | “42·0 (22·0 to NE)” |
| Almost complete or complete symptom relief, hazard ratio (95% CI) | “5·09 (2·81 to 9·22)” | “2·25 (1·19 to 4·27)” | “2·65 (1·61 to 4·38)” | Not applicable |
| Almost complete or complete symptom relief, p value | Not reported | “0·013” | “<0·0001” | Not applicable |

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “Primary and secondary endpoints in the modified intention-to-treat analysis set”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.8.3-7"></a>

###### Key secondary endpoints: change in MSCS score and TOS at 4 hours, deucrictibant 10, 20, and 30 mg versus placebo, mITT analysis set

| Endpoint and measure | Deucrictibant 10 mg | Deucrictibant 20 mg | Deucrictibant 30 mg | Placebo |
| --- | --- | --- | --- | --- |
| MSCS, attacks | “32” | “26” | “27” | “40” |
| MSCS, mean change from pre-treatment (SD) | “−1·08 (0·13)” | “−0·91 (0·14)” | “−0·68 (0·14)” | “−0·29 (0·11)” |
| MSCS, LSM difference vs placebo (95% CI) | “−0·79 (−1·11 to −0·46)” | “−0·61 (−0·97 to −0·26)” | “−0·39 (−0·73 to −0·04)” | Not applicable |
| MSCS, p value | Not reported | “0·0008” | “0·029” | Not applicable |
| TOS, attacks | “32” | “25” | “28” | “40” |
| TOS, mean (SD) score | “57·03 (58·63)” | “62·67 (36·09)” | “68·75 (38·86)” | “−2·71 (62·49)” |
| TOS, LSM difference vs placebo (95% CI) | “64·13 (40·35 to 87·91)” | “62·69 (36·71 to 88·67)” | “71·06 (46·09 to 96·03)” | Not applicable |
| TOS, p value | Not reported | “<0·0001” | “<0·0001” | Not applicable |

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “Primary and secondary endpoints in the modified intention-to-treat analysis set”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “Changes greater than the minimal clinically important differences in MSCS score (–0·30) and mean TOS (30) were observed for deucrictibant-treated attacks at 4 h, but not for placebo-treated attacks (table 2; appendix p 23).”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.8.3-8"></a>

###### Symptom resolution within 24 hours without rescue medication, deucrictibant 20 and 30 mg versus placebo

> “The proportion of attacks with almost complete or complete symptom resolution within 24 h without rescue medication use was 71% (20 of 28) for deucrictibant 20 mg, 74% (23 of 31) for deucrictibant 30 mg, and 16% (eight of 51) for placebo (appendix p 12).”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.8.3-9"></a>

###### Rescue medication use within 12, 24, and 48 hours, deucrictibant 10, 20, and 30 mg versus placebo, mITT analysis set

| Window and measure | Deucrictibant 10 mg | Deucrictibant 20 mg | Deucrictibant 30 mg | Placebo |
| --- | --- | --- | --- | --- |
| Within 12 h, attacks with rescue medication, n (%) | “7 (19%)” | “3 (11%)” | “2 (7%)” | “31 (61%)” |
| Within 12 h, OR vs placebo (95% CI) | “0·15 (0·06 to 0·37)” | “0·08 (0·02 to 0·35)” | “0·04 (0·01 to 0·18)” | Not applicable |
| Within 24 h, attacks with rescue medication, n (%) | “9 (24%)” | “3 (11%)” | “4 (13%)” | “37 (73%)” |
| Within 24 h, OR vs placebo (95% CI) | “0·12 (0·05 to 0·29)” | “0·05 (0·01 to 0·19)” | “0·06 (0·02 to 0·18)” | Not applicable |
| Within 48 h, attacks with rescue medication, n (%) | “9 (24%)” | “4 (14%)” | “5 (16%)” | “37 (73%)” |
| Within 48 h, OR vs placebo (95% CI) | “0·12 (0·05 to 0·29)” | “0·07 (0·02 to 0·24)” | “0·07 (0·02 to 0·22)” | Not applicable |

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “Primary and secondary endpoints in the modified intention-to-treat analysis set”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “A lower proportion of deucrictibant-treated versus placebo-treated attacks used rescue medication within 12 h, 24 h, and 48 h (table 2; figure 3A) and the median time to first rescue medication use was non-evaluable following deucrictibant treatment and 6·0 h (95% CI 4·4 to 13·1) following placebo treatment (figure 3B). Rescue medications used were icatibant, plasma-derived C1 inhibitor, and recombinant human C1 inhibitor.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.8.3-10"></a>

###### Rescue medication use in the top-line data, December 2022, deucrictibant 10, 20, and 30 mg versus placebo

> “December 8, 2022”
> “today announced positive top-line data from the RAPIDe-1 Phase 2 clinical study”
> “Participants on PHVS416 also used substantially less rescue medication compared to placebo (10 mg=18.9%, p<0.00011; 20 mg=10.7%, p=0.0007†; 30 mg=6.5%, p<0.0001†, placebo=60.8%).”

Source: [Pharvaris RAPIDe-1 topline press release (2022)](https://www.sec.gov/Archives/edgar/data/1830487/000156459022039123/phvs-ex991_935.htm)

<a id="topic-3.1.2.8.3-11"></a>

###### Time to onset of primary symptom relief by 30% VAS reduction, registry results, participants with evaluable data

| Group | Participants | Median time, h (95% CI) |
| --- | --- | --- |
| Deucrictibant 10 mg | “21” | “2.0” (“1.4” to “2.4”) |
| Deucrictibant 20 mg | “16” | “3.0” (“1.9” to “4.1”) |
| Deucrictibant 30 mg | “20” | “2.9” (“1.9” to “3.9”) |
| Placebo | “51” | “23.3” (“6.1” to “NA”) |

Source: [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211)

> “Time to Onset of Primary Symptom Relief Assessed by a 30% Reduction in the VAS for the Primary Symptom”
> “Part I efficacy data not collected, consistent with and pre-specified in the study protocol. Includes all participants with evaluable data who completed the relevant assessment time point.”

Source: [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211)

<a id="topic-3.1.2.8.3-12"></a>

###### Post hoc time to end of progression, deucrictibant 10, 20, and 30 mg versus placebo, 147 attacks in 62 participants

> “The EoP analysis included 147 qualifying HAE attacks treated by 62 participants with double-blinded placebo or deucrictibant IR capsule 10, 20, or 30 mg.”
> “Attacks treated with deucrictibant IR capsule (all dose groups) achieved EoP at a median time of 25-26 minutes vs 20 hours for attacks treated with placebo (Table 1 and Figure 2).”
> “Within 24 hours after treatment, 78.4%, 89.3%, and 93.5% of HAE attacks treated with deucrictibant IR capsule 10, 20, and 30 mg, respectively, achieved EoP vs 29.4% of the attacks treated with placebo (Table 1 and Figure 3).”

Source: [Riedl et al. (2023c)](https://ir.pharvaris.com/static-files/0bae214b-7ff8-49ec-8340-1bb60a5935b9)

<a id="topic-3.1.2.8.3-13"></a>

###### Results by attack location: abdominal, peripheral, and combined attacks

> “A higher proportion of attacks primarily occurring in the abdominal area were treated with deucrictibant 10 mg than with other doses or placebo (appendix p 11).”
> “For attacks with cutaneous or abdominal manifestations, or both, shorter times to symptom relief and resolution were consistently observed with deucrictibant compared with placebo (appendix pp 13–14).”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “In these post-hoc analyses, treatment VAS-3 outcomes were analysed according to attack location, i.e., abdominal (individual VAS >0 for abdominal pain), peripheral (individual VAS >0 for skin swelling and/or skin pain) or both”
> “In post-hoc analyses of treatment outcomes by attack location, deucrictibant IR capsule demonstrated consistent rapid onset of symptom relief and resolution of HAE attacks with abdominal, peripheral and combined (abdominal and peripheral) attack location”

Source: [Valerieva et al. (2023)](https://ir.pharvaris.com/static-files/6555035a-ed16-406c-a522-2eb966f73df4)

<a id="topic-3.1.2.8.3-14"></a>

###### Time from symptom onset to treatment

> “Approximately half the study-drug-treated attacks were treated within 90 min of reported onset of symptoms.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.8.3-15"></a>

###### Final analysis of 165 attacks

> “The final analysis included 165 attacks, with nine additional attacks that occurred after data cutoff for the primary analysis.”
> “Efficacy and safety results (appendix pp 16–20) were comparable to those of the primary analysis.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.8.3-16"></a>

###### Company characterization of efficacy across all three doses

> “In our Phase 2 placebo-controlled trial evaluating the efficacy and tolerability of deucrictibant IR capsules for the on-demand treatment of attacks in patients with HAE type 1 and 2 (RAPIDe-1), a statistically significant and clinical meaningful reduction of the patient-reported symptoms of HAE was observed for the attacks treated with all doses of deucrictibant (10, 20, 30 mg) compared to placebo-treated attacks.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-3.1.2.8.3-17"></a>

###### Part 1 pharmacokinetics relative to EC85, 12 participants with sampling

> “Pharmacokinetics were assessed in samples collected from 12 patients during Part 1.”
> “After administration of a single dose of the immediate-release capsule formulation, mean plasma levels of deucrictibant reached the drug concentration estimated to provide 85% maximal response (EC85; above which clinical effects are anticipated based on icatibant studies)”
> “of 13·8 ng/mL within 15-30 min of drug administration and were maintained for 8 h or longer (appendix p 24).”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “PHA121 was absorbed with mean plasma levels reaching the threshold of therapeutic exposure >EC85 (13.8 ng/mL) within 15-30 minutes from PHVS416 administration. Mean plasma levels of PHA121 were maintained >EC85 for approx. 8 hours at 10 mg or 20 mg doses and for >10 hours at 30 mg dose (Figure 2).”

Source: [Maurer et al. (2023a)](https://ir.pharvaris.com/static-files/351671e4-35b8-4bc3-a50d-ef96e17059ab)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.2.8.4-1"></a>

###### TSQM domain scores at 48 hours, registry results, participants with evaluable data

| Group | Participants | Effectiveness, mean (SD) | Convenience, mean (SD) | Satisfaction, mean (SD) |
| --- | --- | --- | --- | --- |
| Deucrictibant 10 mg | “21” | “79.17” (“23.179”) | “80.56” (“16.569”) | “82.50” (“18.907”) |
| Deucrictibant 20 mg | “16” | “70.45” (“30.290”) | “83.08” (“23.096”) | “80.68” (“29.702”) |
| Deucrictibant 30 mg | “20” | “72.92” (“23.085”) | “77.55” (“20.229”) | “76.74” (“22.113”) |
| Placebo | “51” | “65.38” (“23.532”) | “76.07” (“27.441”) | “64.10” (“24.623”) |

Source: [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211)

> “Treatment Satisfaction Questionnaire for Medication Scores at 48 Hours Post-treatment”
> “Part I efficacy data not collected, consistent with and pre-specified in the study protocol. Includes all participants with evaluable data who completed the relevant assessment time point.”

Source: [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211)

<a id="topic-3.1.2.8.4-2"></a>

###### TSQM reporting in the publication

> “Treatment Satisfaction Questionnaire for Medication (TSQM) score, were other lower-ranked secondary endpoints and will be reported elsewhere.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### Part 1 adverse events in the attack-free state, safety analysis set of 72 participants

> “In Part 1, eight (11%) of 72 patients in the safety analysis set reported treatment-emergent adverse events within 5 days post-treatment, with two mild events of nausea and headache considered treatment-related (table 3). The most common treatment-emergent adverse events in two or more patients were headache (two [8%] of 25) and nasopharyngitis (two [8%] of 25) in the deucrictibant 30 mg group.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.8.5-2"></a>

###### Part 2 adverse events in treated attacks, safety analysis set of 156 attacks

> “In Part 2, the safety analysis set included 156 attacks treated with deucrictibant 10 mg, 20 mg, 30 mg, or placebo. No single treatment-emergent adverse event was reported by two or more patients in any treatment group. Three moderate treatment-related treatment-emergent adverse events of nausea, vomiting, and fatigue were reported in a single patient (one [5%] of 22) approximately 20 h after deucrictibant 30 mg administration for one (3%) attack with cutaneous symptoms at onset. Events resolved less than 2 h following standard treatment for nausea and vomiting. One treatment-related event of blister on fingers was reported for one (2%) of 53 placebo-treated attacks.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.8.5-3"></a>

###### Treatment-emergent adverse events within 5 days by part and dose, safety analysis set

| Event | Part 1, 10 mg (n=23) | Part 1, 20 mg (n=24) | Part 1, 30 mg (n=25) | Part 2, 10 mg (38 attacks; n'=21) | Part 2, 20 mg (29 attacks; n'=16) | Part 2, 30 mg (36 attacks; n'=22) | Part 2, placebo (53 attacks; n'=53) |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Any treatment-emergent adverse event | “2 (9%)” | “2 (8%)” | “4 (16%)” | “3 (8%)”, “3 (14%)” | “1 (3%)”, “1 (6%)” | “2 (6%)”, “2 (9%)” | “3 (6%)”, “3 (6%)” |
| Any treatment-related treatment-emergent adverse event | “1 (4%)” | “1 (4%)” | “0” | “0” | “0” | “1 (3%)”, “1 (5%)” | “1 (2%)”, “1 (2%)” |

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “Safety outcomes in the safety analysis set”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “Data shown are the number of attacks with an adverse event that started after the administration of the study drug and before the next administration or end of study, whichever was earlier, including only those adverse events that began within 5 days post-treatment of attack.”
> “Data shown are the number of patients with an adverse event that started after the administration of the study drug and before the next administration or end of study, whichever was earlier, including only those adverse events that began within 5 days post-treatment of attack.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.8.5-4"></a>

###### Severe, serious, and discontinuation events, laboratory, ECG, and vital signs

> “No severe (grade 3), life-threatening (grade 4), or fatal (grade 5) treatment-emergent adverse events were reported. Additionally, no treatment-emergent adverse events were reported that were serious, led to discontinuation of treatment or from the study, or were associated with changes in laboratory or ECG parameters or vital signs (table 3).”
> “No severe, serious, or treatment-limiting adverse reactions occurred in patients receiving deucrictibant. Adverse reactions were mild or moderate and resolved spontaneously or after standard treatment.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.8.5-5"></a>

###### Registry adverse event counts by part and treatment group

| Event group | Deaths | Serious adverse events | Other adverse events |
| --- | --- | --- | --- |
| Part I, 10 mg (participants) | “0” of “23” | “0” of “23” | “2” of “23” |
| Part I, 20 mg (participants) | “0” of “24” | “0” of “24” | “2” of “24” |
| Part I, 30 mg (participants) | “0” of “25” | “0” of “25” | “4” of “25” |
| Part II, 10 mg (study drug treated attacks) | “0” of “38” | “0” of “38” | “3” of “38” |
| Part II, 20 mg (study drug treated attacks) | “0” of “29” | “0” of “29” | “1” of “29” |
| Part II, 30 mg (study drug treated attacks) | “0” of “36” | “0” of “36” | “2” of “36” |
| “Part II Placebo” | “0” of “53” | “0” of “53” | “4” of “53” |

Source: [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211)

> “All AEs (including SAEs) recorded from the time of signing informed consent until the end-of-study visit. Timeframe for reporting adverse events: 5 days post-treatment.”

Source: [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211)

<a id="topic-3.1.2.8.5-6"></a>

###### Treatment-related adverse events in the top-line data and a congress poster

> “today announced positive top-line data from the RAPIDe-1 Phase 2 clinical study”
> “PHVS416 was generally well tolerated with no treatment-related serious adverse events and no adverse events leading to treatment discontinuation. In the non-attack phase, two treatment-related adverse events were experienced by two patients; in the attack treatment phase, three treatment-related adverse events were reported for one attack treated with PHVS416 30mg (2.8%) and one treatment-related adverse event was reported for one attack treated with placebo (1.9%).”

Source: [Pharvaris RAPIDe-1 topline press release (2022)](https://www.sec.gov/Archives/edgar/data/1830487/000156459022039123/phvs-ex991_935.htm)

> “PHVS416 was well-tolerated with 3 treatment-related adverse events (TRAEs) reported for 1 PHVS416 30mg-treated attack (2.8%) and 1 TRAE reported for 1 placebo-treated attack (1.9%), no serious TRAEs or AEs of severe severity, no AEs leading to treatment discontinuation, and no TRAEs of laboratory or ECG parameters, vital signs (Table 4).”
> “Table 4. Treatment-related adverse events within 48 hours after administration of study drug”
> “Presented at the 2023 American Academy of Allergy Asthma and Immunology Annual Meeting (AAAAI 2023)”

Source: [Maurer et al. (2023a)](https://ir.pharvaris.com/static-files/351671e4-35b8-4bc3-a50d-ef96e17059ab)

<a id="topic-3.1.2.8.5-7"></a>

###### Absence of injection-site reactions with oral administration

> “Antagonism of bradykinin B2 receptor was not associated with risks of serious adverse reactions in randomised controlled trials of subcutaneous icatibant nor in its use in clinical practice;”
> “the most common adverse effects were injection-site reactions, which are avoided with orally administered deucrictibant.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

- The authors stated that “Limitations of the RAPIDe-1 trial include the absence of randomisation of attacks according to location and severity”; a higher proportion of attacks primarily in the abdominal area were treated with 10 mg than with other doses or placebo.
- Attacks with vomiting or involving the internal head or neck, including laryngeal attacks, were excluded from treatment, and “reoccurrence of attack symptoms following treatment was not evaluated as a predefined endpoint”.
- The population was limited to adults aged 18 to 75 years with hereditary angioedema type 1 or 2 who were not receiving long-term prophylaxis. Patients with abnormal hepatic or renal function, users of moderate or potent CYP3A4 inhibitors or inducers, and pregnant or breastfeeding women were excluded. In the mITT analysis set, 60 (97%) of 62 participants were White.
- The primary analysis was done before all enrolled participants had treated three attacks; the final analysis of 165 attacks was descriptive. The primary efficacy analysis included 62 of 74 randomized participants, with 28 to 37 attacks per deucrictibant dose. In the registry participant flow, Part II was completed by 16 of 24, 12 of 24, and 12 of 25 participants in the 10 mg, 20 mg, and 30 mg cohorts.
- The 10 mg group had no multiplicity control and was analysed descriptively. The registry notes that within-participant correlation was not accounted for in the Kaplan-Meier medians. End of progression and outcomes by attack location were post-hoc analyses.
- TSQM and other lower-ranked secondary endpoints are to be reported elsewhere. In August 2022 the FDA placed US trials on clinical hold, and only 2 remaining US participants were permitted to complete treatment of a final attack.

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext); [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211); [Riedl et al. (2023c)](https://ir.pharvaris.com/static-files/0bae214b-7ff8-49ec-8340-1bb60a5935b9); [Valerieva et al. (2023)](https://ir.pharvaris.com/static-files/6555035a-ed16-406c-a522-2eb966f73df4); [Pharvaris RAPIDe-1 topline press release (2022)](https://www.sec.gov/Archives/edgar/data/1830487/000156459022039123/phvs-ex991_935.htm); [Riedl et al. (2023a)](https://ir.pharvaris.com/static-files/b15c3784-03fe-4925-aada-1331942c144e)

<a id="heading-3.1.3"></a>

#### 3.1.3 RAPIDe-2

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Registry objective: long-term safety and efficacy of on-demand treatment

> “This study evaluates the safety and efficacy of long-term on-demand treatment with orally administered deucrictibant for acute hereditary angioedema (HAE) attacks, including laryngeal attacks.”

Source: [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105)

<a id="topic-3.1.3.1-2"></a>

###### Main and secondary objectives in the EU register record

> “To evaluate the safety of long-term on-demand treatment with PHA-022121 for acute hereditary angioedema (HAE) attacks including laryngeal attacks.”
> “To evaluate the maintenance of PHA-022121 efficacy in achieving symptom relief for any subsequent acute HAE attacks including laryngeal attacks,”
> “To evaluate the proportion of PHA-022121-treated attacks requiring a second dose of PHA-022121 to achieve symptom relief.”

Source: [EU Clinical Trials Register 2021-006906-58](https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-006906-58/ES)

<a id="topic-3.1.3.1-3"></a>

###### Objective of the Part A final analysis

> “To evaluate the long-term safety and efficacy of deucrictibant immediate-release (IR) capsule for on-demand treatment of repeat HAE attacks in the RAPIDe-2 extension study.”

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

<a id="topic-3.1.3.1-4"></a>

###### Objective of the post hoc upper airway and laryngeal attack analysis

> “Evaluate the safety and efficacy of deucrictibant immediate-release (IR) capsule for on-demand treatment of upper airway, including laryngeal, HAE attacks.”

Source: [Anderson et al. (2025b)](https://ir.pharvaris.com/static-files/2f27144c-943d-44d3-8994-259620304029)

<a id="topic-3.1.3.1-5"></a>

###### Objective of the post hoc durability-of-response analysis

> “To assess the durability of effects following a single dose of deucrictibant immediate-release (IR) capsule for treatment of HAE attacks in the placebo-controlled RAPIDe-1 trial (NCT04618211)* and in the RAPIDe-2 open-label long-term extension study (NCT05396105)*.”

Source: [Jacobs et al. (2025)](https://ir.pharvaris.com/static-files/0dcd8b83-ac4a-4fed-8d4e-632df4720b2c)

<a id="topic-3.1.3.1-6"></a>

###### Purpose stated by the company

> “In addition, we are also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Registry dates, status, and number of locations

| Field | Reported value |
| --- | --- |
| Recruitment status | “Enrolling by invitation” |
| Study start (actual) | “2022-12-28” |
| Primary completion (estimated) | “2027-06” |
| Study completion (estimated) | “2027-06” |
| First posted | “2022-05-31” |
| Last update posted | “2026-07-21” |
| Locations | “This study has 60 locations” |

Source: [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105)

<a id="topic-3.1.3.2-2"></a>

###### Sites anticipated in the European Economic Area

> “Number of sites anticipated in the EEA”
> “13”

Source: [EU Clinical Trials Register 2021-006906-58](https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-006906-58/ES)

<a id="topic-3.1.3.2-3"></a>

###### Study status in the annual report

> “The RAPIDe-2 study is still ongoing.”
> “Phase 2/3, Extension Study to evaluate the safety of long-term on-demand treatment with deucrictibant for acute HAE attacks”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Registry design details

| Field | Reported value |
| --- | --- |
| Phase | “Phase 2” and “Phase 3” |
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105)

<a id="topic-3.1.3.3-2"></a>

###### Two parts: dose-blinded Part A and open-label Part B

> “Part A of the study will enroll adult participants from Study PHA022121-C201. The double-blind treatment assignment from Study PHA022121-C201 will be maintained.”
> “Part B is open-label treatment and includes participants rolling over from Part A, participants from Study PHA022121-C201 who did not participate in Part A, participants aged 12 years and older with HAE type I, type II, or HAE-nC1INH rolling over from Study PHA022121-C306, and deucrictibant treatment naïve adult participants with HAE-nC1INH who elect to participate in this extension study and meet the eligibility requirements.”

Source: [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105)

<a id="topic-3.1.3.3-3"></a>

###### Part A design and treatment of upper airway attacks

> “In Part A of RAPIDe-2, participants remained blinded to their dose of deucrictibant (10 mg, 20 mg, 30 mg) but were able to treat every attack with active study drug. In the extension study, participants were able to treat upper airway attacks, including laryngeal attacks.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-3.1.3.3-4"></a>

###### Phase 2/3 long-term extension with scheduled assessments

> “a two-part, Phase 2/3 long-term extension study.”
> “Data collection: pre-specified at pre-treatment, hourly for 6 hours, and at 8, 12, 24, and 48 hours post-treatment.”

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

<a id="topic-3.1.3.3-5"></a>

###### Study code: C303 in the registry, C201 in one annual report heading

> “PHA022121-C303”

Source: [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105)

> “RAPIDe-2 Phase 2/3 On-Demand Long-Term Extension (C201)”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Part A: adults who completed RAPIDe-1, without long-term prophylaxis

> “Part A eligible participants: adults who completed RAPIDe-1 (NCT04618211).”
> “Part A prophylaxis: no long-term HAE prophylaxis treatment was allowed. Recent use of long-term HAE prophylaxis treatment prior to screening was allowed provided a pre-specified washout period was observed.”

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

<a id="topic-3.1.3.4-2"></a>

###### Registry inclusion: participants from RAPIDe-1 and RAPIDe-3, including adolescents

> “For participants from Study C201, received at least one dose of study drug (including the non-attack visit) in Study C201. For participants from Study C306, participant was randomized (and for adolescent participants ≥12 to <18 years received a dose of study drug in a non-attack state at Visit 1) and completed Study C306, with 2 attacks treated, or after closure of that study by the Sponsor.”
> “12 Years and older”

Source: [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105)

<a id="topic-3.1.3.4-3"></a>

###### Registry inclusion: treatment-naive adults with HAE with normal C1 inhibitor

> “Adult participants with HAE type III (HAE-nC1INH) who are deucrictibant-treatment naïve, must meet all of the following:”
> “Documented effective attack symptom relief with on-demand icatibant treatment.”
> “A history of at least 1 HAE attack in the last 3 months prior to Screening”

Source: [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105)

<a id="topic-3.1.3.4-4"></a>

###### Registry exclusion: lanadelumab, washout periods, and strong CYP3A4 modulators

> “Use of lanadelumab for long-term HAE prophylactic therapy within 12 weeks prior to enrollment in Part A.”
> “2-week washout period before enrollment should be respected for participants who have used any C1-INH product, oral kallikrein inhibitors, attenuated androgens, or anti-fibrinolytics for long-term prophylactic HAE therapy.”
> “Use of concomitant medications that are strong CYP3A4 inhibitors (e.g., clarithromycin, erythromycin, itraconazole, ketoconazole, ritonavir) or strong CYP3A4 inducers (e.g., carbamazepine and phenytoin).”

Source: [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105)

<a id="topic-3.1.3.4-5"></a>

###### Part B: stable long-term prophylaxis permitted

> “If a participant is receiving long-term prophylactic therapy with a medication indicated for HAE:, eg, plasma-derived C1INH, danazol at less than or equal to 200 mg/day, antifibrinolytics, berotralstat, or lanadelumab, they must be on a stable dose and regimen for at least 3 months before screening and intends to remain on the same dose for the duration of the study.”

Source: [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105)

<a id="topic-3.1.3.4-6"></a>

###### EU register exclusion: QTcF prolongation

> “Presence of any medical condition that could interfere with the assessment of safety or efficacy or negatively affect the patient’s safety, including clinically significant abnormal ECG, most notably a QTcF > 470 ms (for females) or > 450 ms (for males), cardiovascular disease, abnormal liver function and abnormal kidney function.”

Source: [EU Clinical Trials Register 2021-006906-58](https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-006906-58/ES)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Registry arms: blinded dose in Part A, open-label soft capsules in Part B

> “Participants will receive the dose of deucrictibant they were randomized to in the PHA022121-C201 study (low, medium, or high dose, each consisting of 3 capsules of deucrictibant or matching placebo) for oral use for on-demand treatment of HAE attacks.”
> “Participants will receive deucrictibant soft capsules for oral use for on-demand treatment of HAE attacks.”

Source: [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105)

<a id="topic-3.1.3.5-2"></a>

###### Second dose and rescue medication rules

> “In RAPIDe-2, a second dose was permitted ≥4 hours after first dose if symptoms persisted or progressed. If symptoms still persisted or progressed after the second dose, rescue medication was permitted. For upper airway attacks with inadequate response or symptom recurrence ≥4 hours after first dose, only rescue medication was permitted.”

Source: [Jacobs et al. (2025)](https://ir.pharvaris.com/static-files/0dcd8b83-ac4a-4fed-8d4e-632df4720b2c)

<a id="topic-3.1.3.5-3"></a>

###### Part A results: combined dose group of 10, 20, and 30 mg

> “Data for combined dose group shown (deucrictibant 10 mg, 20 mg, and 30 mg).”

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Primary endpoint: long-term safety of on-demand use

> “The primary endpoint of the study is to evaluate the long-term safety of deucrictibant as an on-demand agent; secondary endpoints of efficacy were measured using patient global impression of change (PGI-C) and patient global impress of severity (PGI-S) patient reported outcome (PRO) scales.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-3.1.3.6.1-2"></a>

###### Registry primary outcome measures and time frame

> “Treatment-emergent Adverse Events (TEAEs), treatment-related TEAEs, treatment-emergent serious adverse events (TESAEs), treatment-related TESAEs, and TEAEs leading to deucrictibant discontinuation”
> “From enrollment through study completion, up to 54 months (dependent on time of enrollment).”
> “Descriptive in nature, no formal statistical hypothesis testing will be performed.”

Source: [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105)

<a id="topic-3.1.3.6.1-3"></a>

###### Safety components of the primary endpoint

> “Primary endpoint: safety, including treatment-emergent adverse events (TEAEs), clinical laboratory tests, vital signs, and electrocardiogram (ECG) findings.”
> “Secondary endpoints: efficacy endpoints using patient-reported outcome tools.”

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

<a id="topic-3.1.3.6.1-4"></a>

###### Secondary endpoints in the registry

> “Time to onset of symptom relief, defined as Patient Global Impression of Change (PGI-C) rating of at least "a little better" for 2 consecutive timepoints within 12 hours post-treatment”
> “Time to substantial symptom relief by Patient Global Impression of Severity (PGI-S), defined as achieving ≥1 point reduction in PGI-S from pre-treatment for 2 consecutive timepoints within 12 hours post-treatment”
> “Proportion of deucrictibant-treated attacks requiring rescue medication within 24 hours post-treatment”
> “Time to onset of symptom relief, assessed by a ≥30% reduction in VAS-3/ VAS-5 (Part A) or AMRA (Part B) composite score from the pre-treatment score”

Source: [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105)

<a id="topic-3.1.3.6.1-5"></a>

###### Censoring rules for rescue medication

> “If rescue medication used within 14.5 hours post-treatment, time to event was censored at 14.5 hours regardless of whether event occurred within 12 hours post-treatment.”
> “Rescue medication use within 33.5 hours post-treatment was regarded as not achieving complete attack resolution at 24 hours.”

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

<a id="topic-3.1.3.6.1-6"></a>

###### Post hoc endpoint: durability of response and symptom reoccurrence

> “Durability of treatment response: the achievement and maintenance of serial milestones of symptom relief and resolution without reoccurrence of symptoms following a single dose of deucrictibant only.”
> “Symptom reoccurrence: following the achievement of each efficacy milestone, symptom reoccurrence was evaluated as any instance where the milestone was no longer being met within 24 hours.”

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

<a id="topic-3.1.3.6.1-7"></a>

###### Post hoc definition of upper airway attacks

> “Upper airway attacks confirmed by investigators as per protocol definition if following manifestations of an attack were reported: swelling of the lips/tongue or any sensation of lump in the throat, difficulty swallowing, or voice change.”
> “Difficulty swallowing and voice change as manifestations of an attack were assessed prior to treatment using the 5-symptom composite Angioedema syMptom Rating scAle (AMRA-5).”

Source: [Anderson et al. (2025b)](https://ir.pharvaris.com/static-files/2f27144c-943d-44d3-8994-259620304029)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Planned enrollment in the registry

> “Enrollment (Estimated)”
> “150”

Source: [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105)

<a id="topic-3.1.3.7.1-2"></a>

###### Planned number of participants in the EU register record

> “Planned number of subjects to be included”
> “In the whole clinical trial”
> “72”

Source: [EU Clinical Trials Register 2021-006906-58](https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-006906-58/ES)

<a id="topic-3.1.3.7.1-3"></a>

###### Part A analyzed: 465 attacks in 19 participants

> “RAPIDe-2 Part A included 465 attacks from 19 participants.”

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

> “RAPIDe-2 includes 465 attacks from 19 participants, 14 of the attacks were upper airway attacks.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-3.1.3.7.1-4"></a>

###### Upper airway attacks: 14 attacks in seven participants

> “465 attacks were treated by 19 participants.”
> “14 upper airway attacks, including laryngeal, were treated for seven participants.”
> “Difficulty in swallowing and/or voice change were reported as manifestations of six attacks prior to treatment.”

Source: [Anderson et al. (2025b)](https://ir.pharvaris.com/static-files/2f27144c-943d-44d3-8994-259620304029)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

###### Safety and modified intention-to-treat analysis sets (Part A)

> “Participants who received at least one dose of deucrictibant IR capsule in the study.”
> “Modified intention-to-treat analysis set: participants who treated at least one attack with deucrictibant IR capsule and non-missing Patient Global Impression of Change (PGI-C) results from at least one post-treatment timepoint.”

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

<a id="topic-3.1.3.7.2-2"></a>

###### Evaluable attacks for PGI-C and PGI-S endpoints

> “457 attacks have ≥1 post-treatment PGI-C result.”
> “449 attacks have non-missing pre-treatment PGI-S and ≥1 post-treatment PGI-S.”
> “Within-participant correlation was not accounted for in all Kaplan–Meier estimates.”

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

<a id="topic-3.1.3.7.2-3"></a>

###### Baseline values carried from RAPIDe-1

> “Study baseline refers to results at the screening or enrollment visit of RAPIDe-2 Part A. For parameters whose values remain constant over time, baseline values from RAPIDe-1 were used.”

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### Entry from RAPIDe-1

> “Following treatment of participation in RAPIDe-1, participants were eligible to either join the Phase 2 randomized clinical trial of deucrictibant for the prevention of HAE attacks (CHAPTER-1) or roll over to the long-term extension on-demand study (RAPIDe-2).”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-3.1.3.8.1-2"></a>

###### Part A: no discontinuations, withdrawals, or deaths due to adverse events

> “The final RAPIDe-2 Part A results included 465 HAE attacks treated with deucrictibant by 19 participants.”

Source: [Jacobs et al. (2025)](https://ir.pharvaris.com/static-files/0dcd8b83-ac4a-4fed-8d4e-632df4720b2c)

> “No TEAEs leading to treatment discontinuation, study withdrawal, or death.”

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

###### Part A participants, combined dose group (N=19)

| Characteristic | Deucrictibant IR capsule, combined dose group |
| --- | --- |
| Age in years, mean (SD) | “44.4 (17.6)” |
| Sex: male / female, n (%) | “7 (36.8) / 12 (63.2)” |
| Race: White / other, n | “18 / 1” |
| BMI, mean (SD) | “26.8 (4.0)” |
| Years since HAE diagnosis, mean (SD) | “23.3 (15.2)” |
| HAE-1, n (%) | “17 (89.5)” |
| HAE-2, n (%) | “2 (10.5)” |

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

<a id="topic-3.1.3.8.2-2"></a>

###### Participants with and without upper airway attacks

| Characteristic | With ≥1 upper airway attack (n=7) | Without upper airway attacks (n=12) |
| --- | --- | --- |
| Age in years, mean (SD) | “46.0 (19.5)” | “43.4 (17.2)” |
| Sex: male / female, n (%) | “4 (57) / 3 (43)” | “3 (25) / 9 (75)” |
| Race: White / other, n | “7 / 0” | “11 / 1” |
| BMI, mean (SD) | “27.1 (3.8)” | “26.7 (4.2)” |
| Years since HAE diagnosis, mean (SD) | “20.8 (18.9)” | “24.7 (13.3)” |
| HAE-1, n (%) | “6 (85.7)” | “11 (91.7)” |
| HAE-2, n (%) | “1 (14.3)” | “1 (8.3)” |

Source: [Anderson et al. (2025b)](https://ir.pharvaris.com/static-files/2f27144c-943d-44d3-8994-259620304029)

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### Median time to key efficacy endpoints, Part A (465 attacks)

| Endpoint | Median time | 95% CI |
| --- | --- | --- |
| Onset of symptom relief (PGI-C) | “1.1 hours” | “(1.0, 1.1)” |
| Substantial symptom relief (PGI-C) | “2.5 hours” | “(2.1, 2.9)” |
| Reduction in attack severity (PGI-S) | “2.8 hours” | “(2.3, 2.9)” |
| Complete attack resolution (PGI-S) | “10.6 hours” | “(8.5, 11.5)” |

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

<a id="topic-3.1.3.8.3-2"></a>

###### Median times reported in the annual report

> “Secondary endpoints from the RAPIDe-2 study included time to onset of symptom relief as measured by a PGI-C rating of at least “a little better” for two consecutive timepoints (1.1 hours), time to substantial symptom relief as measured by a PGI-C rating of at least “better” for two consecutive timepoints (2.5 hours), time to reduction in attack severity as measured by at least one level reduction in PGI-S from pre-treatment for two consecutive endpoints (2.8 hours), and time to complete attack resolution as measured by a PGI-S rating of “none” (10.6 hours).”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-3.1.3.8.3-3"></a>

###### Proportion of attacks achieving key endpoints, evaluable attacks (457 PGI-C, 449 PGI-S)

| Endpoint | Proportion of attacks | Attacks |
| --- | --- | --- |
| Onset of symptom relief by 12 hours | “97.8%” | “447/457” |
| Substantial symptom relief by 12 hours | “95.2%” | “435/457” |
| Reduction in attack severity by 12 hours | “96.7%” | “434/449” |
| Complete symptom resolution at 24 hours | “86.9%” | “390/449” |

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

<a id="topic-3.1.3.8.3-4"></a>

###### Attacks treated with a single dose and rescue medication use, evaluable attacks (457)

| Attacks | One dose | Two doses |
| --- | --- | --- |
| Overall | “86.2%” “394/457” | “13.8%” “63/457” |
| Complete attack resolution within 24 hours | “89.2%” “348/390” | “10.8%” “42/390” |

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

> “8 attacks used rescue medication within 24 hours post-treatment.”

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

<a id="topic-3.1.3.8.3-5"></a>

###### Attacks treated with a single dose, all treated attacks (465)

> “of attacks were treated with a single dose of deucrictibant IR capsule in RAPIDe-2”
> “84.9%”
> “(395/465)”

Source: [Jacobs et al. (2025)](https://ir.pharvaris.com/static-files/0dcd8b83-ac4a-4fed-8d4e-632df4720b2c)

<a id="topic-3.1.3.8.3-6"></a>

###### Durability of response after a single dose, post hoc analysis

> “98.3% (344/350)”
> “of attacks achieving onset of symptom relief with a single dose of deucrictibant maintained a durable response”
> “99.2% (382/385)”
> “of attacks achieving complete attack resolution with a single dose of deucrictibant maintained a durable response”

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

> “of attacks that achieved symptom relief and resolution with 1 deucrictibant IR capsule had a durable response without symptom reoccurrence in RAPIDe-2”

Source: [Jacobs et al. (2025)](https://ir.pharvaris.com/static-files/0dcd8b83-ac4a-4fed-8d4e-632df4720b2c)

<a id="topic-3.1.3.8.3-7"></a>

###### Upper airway attacks compared with non-upper airway attacks, post hoc analysis

| Endpoint | Upper airway attacks (n=7 participants) | Non-upper airway attacks in participants with upper airway attacks (n=7) | All non-upper airway attacks (n=19) |
| --- | --- | --- | --- |
| Total number of attacks treated | “14” | “177” | “451” |
| Time to onset of symptom relief, median hours (95% CI) | “1.4 (0.8–3.0)” | “1.0 (1.0–1.2)” | “1.1 (1.0–1.1)” |
| Time to substantial symptom relief, median hours (95% CI) | “3.6 (2.0–6.1)” | “2.7 (2.1–3.0)” | “2.4 (2.1–2.8)” |
| Time to reduction in attack severity, median hours (95% CI) | “1.8 (0.9–3.0)” | “2.1 (2.0–2.8)” | “2.8 (2.4–2.9)” |
| Time to complete attack resolution, median hours (95% CI) | “8.9 (3.9–36.3)” | “8.0 (7.3–10.7)” | “10.6 (8.5–11.5)” |

Source: [Anderson et al. (2025b)](https://ir.pharvaris.com/static-files/2f27144c-943d-44d3-8994-259620304029)

<a id="topic-3.1.3.8.3-8"></a>

###### Upper airway attacks: proportions achieving endpoints, single dose, and rescue use

> “of upper airway attacks achieved onset of symptom relief by 12 hours”
> “of upper airway attacks achieved complete attack resolution at 24 hours”
> “8/12”
> “of upper airway attacks were treated with a single dose of deucrictibant IR capsule”
> “One participant used rescue medication for one upper airway attack and used a single dose of deucrictibant to treat 2 subsequent upper airway attacks.”

Source: [Anderson et al. (2025b)](https://ir.pharvaris.com/static-files/2f27144c-943d-44d3-8994-259620304029)

<a id="topic-3.1.3.8.3-9"></a>

###### Company summary of Part A efficacy

> “In the upper airway attacks treated, there were similar times to relief and resolution of attacks as seen in the full data set. The majority of the attacks were treated with a single dose of deucrictibant and without rescue medication within 24 hours. The final results from Part A of the RAPIDe-2 extension were consistent with the Phase 2 RAPIDe-1 study and provide evidence on the long-term safety and efficacy of deucrictibant IR capsule for treatment of repeat HAE attacks.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Adverse events within 3 days of study drug, Part A (N=19; 465 attacks)

| Adverse events | Deucrictibant IR capsule, combined dose group |
| --- | --- |
| Attacks with any TEAE, n (%) | “12 (2.6)” |
| Treatment-related TEAEs, n | “0” |
| Serious TEAEs, n | “1” |
| Treatment-related serious TEAEs, n | “0” |
| TEAEs leading to study drug discontinuation, study withdrawal, or death, n | “0” |

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

<a id="topic-3.1.3.8.5-2"></a>

###### Serious adverse event unrelated to treatment, and laboratory, vital sign, and ECG findings

> “Tooth caries unrelated to treatment.”
> “No treatment-related TEAEs.”
> “No treatment-related serious or severe TEAEs, no treatment-related TEAEs in laboratory parameters, vital signs, or ECG findings.”

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

<a id="topic-3.1.3.8.5-3"></a>

###### Safety across dose groups in the annual report

> “Deucrictibant was well tolerated across all doses, with no treatment-related treatment-emergent adverse events (TEAEs), with no TEAEs leading to treatment discontinuation, study withdrawal, or death.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-3.1.3.8.5-4"></a>

###### Safety in upper airway and non-upper airway attacks

> “Deucrictibant was generally well tolerated with no treatment-related TEAEs reported across upper airway and non-upper airway attacks.”

Source: [Anderson et al. (2025b)](https://ir.pharvaris.com/static-files/2f27144c-943d-44d3-8994-259620304029)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

- RAPIDe-2 is a single-group study with no control arm, and its registry record lists no masking. In Part A, participants were blinded to dose while every attack was treated with active drug. The registry states the primary safety analysis is “Descriptive in nature, no formal statistical hypothesis testing will be performed”.
- Part A included 19 adults, all from RAPIDe-1, who contributed 465 attacks; long-term prophylaxis was not allowed and 18 of the 19 were White. Results were reported for the combined 10 mg, 20 mg, and 30 mg dose group.
- Denominators vary by endpoint: 457 attacks had post-treatment PGI-C data and 449 had pre-treatment and post-treatment PGI-S data, and the single-dose proportion is reported as 394/457 and as 395/465. “Within-participant correlation was not accounted for in all Kaplan–Meier estimates”.
- Upper airway results rest on 14 attacks in seven participants.
- Rescue medication use within 14.5 hours led to censoring at 14.5 hours, and baseline values for constant parameters were taken from RAPIDe-1.
- Planned enrollment is 150 in ClinicalTrials.gov and 72 in the EU register. “The RAPIDe-2 study is still ongoing”, with primary completion estimated for 2027-06. Part A results come from documents on the company's investor website and the company's annual report, and Part B results are limited to cardiovascular events in 110 participants.

Source: [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105); [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm); [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54); [Jacobs et al. (2025)](https://ir.pharvaris.com/static-files/0dcd8b83-ac4a-4fed-8d4e-632df4720b2c); [Anderson et al. (2025b)](https://ir.pharvaris.com/static-files/2f27144c-943d-44d3-8994-259620304029); [EU Clinical Trials Register 2021-006906-58](https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-006906-58/ES); [Lesage et al. (2026a)](https://ir.pharvaris.com/static-files/832a8830-6fd1-41ac-b767-e1b348388853)

<a id="heading-3.1.4"></a>

#### 3.1.4 PHA121-C001

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy participants

> “PHA121-C001 was a randomized, double-blind, placebo-controlled, single ascending dose and proof-of-mechanism study to examine the safety, tolerability, PK and PD of orally administered PHA121 in healthy subjects.”

Source: [Pharvaris Form F-1/A registration statement (2021)](https://www.sec.gov/Archives/edgar/data/1830487/000119312521023578/d50231df1a.htm)

<a id="topic-3.1.4.1-2"></a>

###### Proof of mechanism through bradykinin challenge

> “Randomized, double-blind, placebo-controlled, single ascending dose to assess safety and proof-of-concept through BK-challenge”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

> “The effect of PHA-022121 cardiovascular changes induced by bradykinin (BK) such as blood pressure (systolic, SBP; diastolic, DBP; mean, MAP), heart rate (HR) and cardiac output (CO) was evaluated in a proof-of-concept study in healthy volunteers.”

Source: [Derendorf et al. (2020)](https://ir.pharvaris.com/static-files/33217945-6893-4f49-8a93-c80ea6fb2a31)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Entry into clinical development with a phase 1 trial in 2019

> “The increase in research and development expenses in 2019 compared to 2018 was due to the progression of PHA121 into clinical development, with a Phase 1 clinical trial initiated in 2019”

Source: [Pharvaris Form F-1/A registration statement (2021)](https://www.sec.gov/Archives/edgar/data/1830487/000119312521023578/d50231df1a.htm)

<a id="topic-3.1.4.2-2"></a>

###### Completion reported in November 2020

> “Data from a recently completed single-ascending-dose Phase 1 study in healthy volunteers, as well as in vitro and ex vivo models, demonstrate rapid exposure and predictable linear pharmacokinetics.”

Source: [Pharvaris ACAAI 2020 press release (2020)](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-presents-clinical-data-acaai-2020-demonstrating-safety)

<a id="topic-3.1.4.2-3"></a>

###### Study status in the annual report

> “Single ascending dose (SAD)”
> “Completed”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Double-blind, placebo-controlled, single ascending dose, first-in-human design

> “PHA-022121 was administered as oral solution in a double-blind placebo-controlled single ascending dose first-in-human study in healthy volunteers”
> “Safety was assessed by physical examination, vital signs, adverse events, safety laboratory and electrocardiogram (ECG) until 72 h post-dosing.”

Source: [Lu et al. (2020)](https://ir.pharvaris.com/static-files/0361cd85-6000-490b-932b-d305e1f3ca1b)

<a id="topic-3.1.4.3-2"></a>

###### Cohorts: pharmacokinetic part 1 and pharmacodynamic part 2

| Cohort | Participants |
| --- | --- |
| Part 1 (PK), 1 mg, fasted | “N=6” |
| Part 1 (PK), 2 mg, fasted | “N=6” |
| Part 1 (PK), 4.5 mg, fasted | “N=6” |
| Part 1 (PK), 12 mg, fasted | “N=6” |
| Part 1 (PK), 22 mg, fasted | “N=6” |
| Part 1 (PK), 22 mg, after high-calorie, high-fat breakfast | “N=6” |
| Part 1 (PK), placebo | “N=12” |
| Part 2 (PD), 12 mg, fasted | “N=8” |
| Part 2 (PD), 22 mg, fasted | “N=8” |
| Part 2 (PD), placebo | “N=4” |

Source: [Lu et al. (2020)](https://ir.pharvaris.com/static-files/0361cd85-6000-490b-932b-d305e1f3ca1b)

<a id="topic-3.1.4.3-3"></a>

###### Bradykinin challenge schedule

> “Bradykinin was injected intravenously before PHA121 to calibrate each subject’s response, and then at 1, 4, 8, 12 and 24 hours after dosing with PHA121. We monitored cardiovascular responses at each time point (see figure above). At the same time, blood samples were drawn for PK assessment.”

Source: [Pharvaris Form F-1/A registration statement (2021)](https://www.sec.gov/Archives/edgar/data/1830487/000119312521023578/d50231df1a.htm)

<a id="topic-3.1.4.3-4"></a>

###### Study code: C001 in the annual report, PHA121-C001 in the registration statement

> “C001”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

> “PHA121-C001 (SAD and BK challenge / SAD-POM)”

Source: [Pharvaris Form F-1/A registration statement (2021)](https://www.sec.gov/Archives/edgar/data/1830487/000119312521023578/d50231df1a.htm)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Healthy volunteers

> “The data in both posters present the pharmacokinetic (PK), pharmacodynamic (PD), and safety profiles of PHA121 in healthy volunteers.”

Source: [Pharvaris ACAAI 2020 press release (2020)](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-presents-clinical-data-acaai-2020-demonstrating-safety)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Single oral doses as an oral solution

> “PHA121 was administered as an oral solution in a double-blind placebo-controlled single-ascending-dose first-in-human study in healthy volunteers.”

Source: [Pharvaris ACAAI 2020 press release (2020)](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-presents-clinical-data-acaai-2020-demonstrating-safety)

<a id="topic-3.1.4.5-2"></a>

###### Bradykinin challenge cohorts: 12 and 22 mg

> “PHA-022121 (12 and 22 mg) was administered orally (p.o.) to 16 healthy volunteers.”
> “Bradykinin injections were administered to induce cardiovascular responses.”

Source: [Derendorf et al. (2020)](https://ir.pharvaris.com/static-files/33217945-6893-4f49-8a93-c80ea6fb2a31)

<a id="topic-3.1.4.5-3"></a>

###### Fed condition: 22 mg after a high-calorie, high-fat breakfast

> “§ after high caloric/high fat (HCHF) breakfast”

Source: [Lu et al. (2020)](https://ir.pharvaris.com/static-files/0361cd85-6000-490b-932b-d305e1f3ca1b)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Safety and Tolerability as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Safety and pharmacokinetics assessed through 72 hours

> “Both PK parameters and safety were assessed until 72 hours post-dosing.”

Source: [Pharvaris ACAAI 2020 press release (2020)](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-presents-clinical-data-acaai-2020-demonstrating-safety)

<a id="topic-3.1.4.6.1-2"></a>

###### Bradykinin challenge as a surrogate for dose selection

> “The bradykinin challenge is administered at specific intervals after the PHA121 or placebo dose, and the inhibition of bradykinin-induced hemodynamic effects is a validated surrogate assessment that was used to select the dose in the original development program for icatibant, as reviewed by FDA and EMA.”
> “More precisely, it was shown that icatibant plasma concentrations with a 75% probability to be above EC50 and a 50% probability to be above EC85 correlate with therapeutic efficacy.”

Source: [Pharvaris Form F-1/A registration statement (2021)](https://www.sec.gov/Archives/edgar/data/1830487/000119312521023578/d50231df1a.htm)

> “Dampened BK-induced effects are closely associated with successful therapeutic outcome for icatibant”

Source: [Derendorf et al. (2020)](https://ir.pharvaris.com/static-files/33217945-6893-4f49-8a93-c80ea6fb2a31)

<a id="topic-3.1.4.6.1-3"></a>

###### Pharmacodynamic outcome definition

> “The pharmacodynamic (PD) outcome variables were measured from 5 min before until 5 min after each BK bolus. A % inhibition-of-the-baseline average-to-peak effect was calculated and used as the PD outcome.”

Source: [Derendorf et al. (2020)](https://ir.pharvaris.com/static-files/33217945-6893-4f49-8a93-c80ea6fb2a31)

<a id="topic-3.1.4.6.1-4"></a>

###### Use of the bradykinin challenge results for later studies

> “Demonstrated proof-of-mechanism”
> “Provided justification of dose selection for on-demand studies”
> “Provided guidance for prophylactic development”

Source: [Lesage et al. (2021)](https://ir.pharvaris.com/static-files/76beb63f-4ccf-482a-933d-d2b47ec4e09d)

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Participants receiving deucrictibant and placebo

> “A total of 52 subjects received single ascending oral doses of PHA121 up to 22 mg. The 16 remaining subjects received placebo.”

Source: [Pharvaris Form F-1/A registration statement (2021)](https://www.sec.gov/Archives/edgar/data/1830487/000119312521023578/d50231df1a.htm)

<a id="topic-3.1.4.7.1-2"></a>

###### Bradykinin challenge participants

> “Two doses (12 and 22 mg) of PHA121 were administered orally to 16 healthy volunteers, followed by bradykinin challenges to induce brief hemodynamic responses.”

Source: [Pharvaris ACAAI 2020 press release (2020)](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-presents-clinical-data-acaai-2020-demonstrating-safety)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

###### Pharmacokinetic and pharmacodynamic modeling of the bradykinin challenge cohorts

> “PHA-022121-induced changes of these BK responses were evaluated with a nonlinear mixed-effect PK/PD model. The results were compared to published results obtained from icatibant (3). PK was analyzed using a two-compartment body model with first-order oral absorption and a lag time. For the PK/PD model a simple Emax-model with a direct link was utilized.”

Source: [Derendorf et al. (2020)](https://ir.pharvaris.com/static-files/33217945-6893-4f49-8a93-c80ea6fb2a31)

<a id="topic-3.1.4.7.2-2"></a>

###### Pharmacokinetic summary statistics

> “# means (standard deviation),  median (range) for tmax”

Source: [Lu et al. (2020)](https://ir.pharvaris.com/static-files/0361cd85-6000-490b-932b-d305e1f3ca1b)

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

###### No withdrawals due to adverse events

> “No adverse event, or AE, was reported as serious, no premature withdrawals due to AEs occurred and no severe AEs were reported.”

Source: [Pharvaris Form F-1/A registration statement (2021)](https://www.sec.gov/Archives/edgar/data/1830487/000119312521023578/d50231df1a.htm)

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

###### Pharmacokinetics: rapid absorption, dose proportionality, and half-life

> “PHA-022121 was very rapidly absorbed and reached peak plasma levels within 30 to 60 minutes after dosing in all subjects under fasted conditions. The systemic exposure was dose proportional with a mean t1/2 ranging from 3.5 to 5.6 h between doses.”

Source: [Lu et al. (2020)](https://ir.pharvaris.com/static-files/0361cd85-6000-490b-932b-d305e1f3ca1b)

> “Less than 1% of the dose was excreted unchanged in urine within 72 hours after administration.”

Source: [Pharvaris Form F-1/A registration statement (2021)](https://www.sec.gov/Archives/edgar/data/1830487/000119312521023578/d50231df1a.htm)

<a id="topic-3.1.4.8.3-2"></a>

###### Pharmacokinetic parameters by dose (N=6 per dose)

| Parameter | 1 mg | 2 mg | 4.5 mg | 12 mg | 22 mg | 22 mg after HCHF breakfast |
| --- | --- | --- | --- | --- | --- | --- |
| Cmax, ng/mL, mean (SD) | “11.1 (4.03)” | “19.8 (3.70)” | “32.9 (7.66)” | “97.3 (28.1)” | “213 (49.5)” | “145 (56.2)” |
| C0.25h, ng/mL, mean (SD) | “5.99 (4.28)” | “12.9 (8.10)” | “13.0 (7.00)” | “60.3 (40.6)” | “143 (85.9)” | “48.3 (53.9)” |
| AUClast, ng.h/mL, mean (SD) | “33.0 (25.9)” | “66.0 (27.0)” | “129 (56.5)” | “369 (194)” | “681 (113)” | “1015 (490)” |
| t1/2, h, mean (SD) | “3.49 (1.32)” | “4.26 (1.91)” | “4.36 (1.29)” | “4.25 (0.831)” | “5.61 (0.707)” | “5.31 (1.54)” |

Source: [Lu et al. (2020)](https://ir.pharvaris.com/static-files/0361cd85-6000-490b-932b-d305e1f3ca1b)

<a id="topic-3.1.4.8.3-3"></a>

###### Food effect at 22 mg

> “Administration of the 22 mg dose with a HCHF breakfast led to a 32% lower Cmax, a 49% higher AUClast, and a delay of median tmax by approximately 2 h.”

Source: [Lu et al. (2020)](https://ir.pharvaris.com/static-files/0361cd85-6000-490b-932b-d305e1f3ca1b)

> “after a 22 mg dose, the mean Cmax of PHA121 was lower (~32%) while AUCinf was higher (~ 42%) when PHA121 was administered after a high calorie, high-fat breakfast (fed conditions) compared to administration under fasted conditions.”

Source: [Pharvaris Form F-1/A registration statement (2021)](https://www.sec.gov/Archives/edgar/data/1830487/000119312521023578/d50231df1a.htm)

<a id="topic-3.1.4.8.3-4"></a>

###### Time to and duration above therapeutic threshold concentrations

> “Plasma levels for PHA-022121 reached therapeutic efficacious threshold concentration (estimated EC50 2.4 ng/mL and EC85 13.8 ng/mL ; see poster P151 (2)) within 15 min for all doses and were maintained for approximately 12 h with doses of 12 and 22 mg.”

Source: [Lu et al. (2020)](https://ir.pharvaris.com/static-files/0361cd85-6000-490b-932b-d305e1f3ca1b)

<a id="topic-3.1.4.8.3-5"></a>

###### Bradykinin challenge: potency relative to icatibant

| Composite average | PHA121 | Icatibant |
| --- | --- | --- |
| EC50 (ng/mL) | “2.4” | “9.5” |
| EC85 (ng/mL) | “13.8” | “53.8” |

Source: [Pharvaris Form F-1/A registration statement (2021)](https://www.sec.gov/Archives/edgar/data/1830487/000119312521023578/d50231df1a.htm)

> “Adjusting for the differences between molecular weight and plasma protein binding, we found that PHA121 is 24-fold more potent (170 pM) in the bradykinin challenge than icatibant (4.1 nM) on a molecule-by-molecule basis, consistent with our preclinical in vitro measurements.”

Source: [Pharvaris Form F-1/A registration statement (2021)](https://www.sec.gov/Archives/edgar/data/1830487/000119312521023578/d50231df1a.htm)

<a id="topic-3.1.4.8.3-6"></a>

###### Bradykinin challenge: modeled duration of effect compared with icatibant 30 mg

| Response | Icatibant 30 mg (s.c.) | PHA121 12 mg (oral) | PHA121 22 mg (oral) |
| --- | --- | --- | --- |
| Diastolic blood pressure, time (h) above EC50 at a 75% confidence level | “6” | “11.5” | “14” |
| Mean arterial blood pressure, time (h) above EC50 at a 75% confidence level | “6” | “12” | “15.5” |
| Heart rate, time (h) above EC50 at a 75% confidence level | “6.5” | “10” | “13” |
| Diastolic blood pressure, time (h) above EC85 at a 50% confidence level | “5.5” | “7.5” | “10” |
| Mean arterial blood pressure, time (h) above EC85 at a 50% confidence level | “5.5” | “7” | “10” |
| Heart rate, time (h) above EC85 at a 50% confidence level | “5.5” | “6.5” | “9.5” |

Source: [Pharvaris Form F-1/A registration statement (2021)](https://www.sec.gov/Archives/edgar/data/1830487/000119312521023578/d50231df1a.htm)

<a id="topic-3.1.4.8.3-7"></a>

###### Authors' conclusions on the bradykinin challenge

> “The investigated single oral doses of PHA-022121 (12 and 22 mg) provide equivalent BK-antagonism for a longer time than a 30 mg s.c. icatibant injection.”

Source: [Derendorf et al. (2020)](https://ir.pharvaris.com/static-files/33217945-6893-4f49-8a93-c80ea6fb2a31)

> “The BK challenge demonstrated that PHA121 potently blocks the effects of bradykinin-induced hemodynamic changes and provided the robust rationale for dose selection in future on-demand and prophylactic HAE trials.”

Source: [Pharvaris Form F-1/A registration statement (2021)](https://www.sec.gov/Archives/edgar/data/1830487/000119312521023578/d50231df1a.htm)

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

###### Adverse events by dose group

| Dose group | Participants | Any AE, n (%) | Any related AE | Any severe AE | Any serious AE |
| --- | --- | --- | --- | --- | --- |
| 1 mg, fasted | “N=6” | “2 (33.3%)” | “0” | “0” | “0” |
| 2 mg, fasted | “N=6” | “1 (16.7%)” | “0” | “0” | “0” |
| 4.5 mg, fasted | “N=6” | “1 (16.7%)” | “0” | “0” | “0” |
| 12 mg, fasted | “N=14” | “5 (35.7%)” | “2 (14.3%)” | “0” | “0” |
| 22 mg, fasted | “N=14” | “2 (14.3%)” | “1 (7.1%)” | “0” | “0” |
| 22 mg after HCHF breakfast | “N=6” | “1 (16.7%)” | “0” | “0” | “0” |
| Placebo | “N=16” | “5 (31.3%)” | “1 (6.3%)” | “0” | “0” |

Source: [Lu et al. (2020)](https://ir.pharvaris.com/static-files/0361cd85-6000-490b-932b-d305e1f3ca1b)

<a id="topic-3.1.4.8.5-2"></a>

###### Adverse event incidence with deucrictibant and placebo

> “In total 17 AEs were reported by 12 out of 52 subjects on active drug versus 7 AEs in 5 out of 16 placebo treated subjects. No serious or severe adverse events occurred. All related adverse events were of mild intensity and resolved rapidly.”
> “No clinically significant changes in safety laboratory parameters, vital signs and ECG parameters were observed.”

Source: [Lu et al. (2020)](https://ir.pharvaris.com/static-files/0361cd85-6000-490b-932b-d305e1f3ca1b)

> “In total, 17 AEs were reported by 12 out of 52 subjects (23%) on study drug versus 7 AEs in 5 out of 16 (31%) placebo-treated subjects.”

Source: [Pharvaris ACAAI 2020 press release (2020)](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-presents-clinical-data-acaai-2020-demonstrating-safety)

<a id="topic-3.1.4.8.5-3"></a>

###### Treatment-related gastrointestinal adverse events and blood pressure

> “In addition, no clinically relevant fluctuations of blood pressure and no orthostatic hypotension linked to PHA121 groups occurred.”
> “Treatment-related AEs were reported for three subjects who received PHA121 (12 or 22 mg), all within the gastrointestinal system and of mild severity: upper abdominal pain, vomiting, and nausea.”

Source: [Pharvaris Form F-1/A registration statement (2021)](https://www.sec.gov/Archives/edgar/data/1830487/000119312521023578/d50231df1a.htm)

<a id="topic-3.1.4.8.5-4"></a>

###### Pooled safety across two single ascending dose studies (1 to 50 mg)

> “PHA-022121 was orally administered in two double-blind, placebo-controlled single ascending dose studies (range 1-50 mg) with pharmacokinetic (PK) and safety follow-up for 72 h.”
> “Adverse events (AEs) were reported by 25% of the subjects in the combined group of all subjects treated with PHA-022121, identical to the 25% incidence with placebo.”
> “All AEs were mild or moderate and subsided rapidly and completely.”

Source: [Crabbé et al. (2021)](https://ir.pharvaris.com/static-files/a5937e81-635a-4808-b099-3a049c87c51b)

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary

- PHA121-C001 enrolled healthy volunteers, who received single doses up to 22 mg given as an oral solution.
- Pharmacokinetic cohorts had six participants per dose, and the food effect was assessed in one cohort of six participants at 22 mg. The higher AUCinf after a high-calorie, high-fat breakfast was reported as “mainly caused by one outlier”, and the AUC increase is reported as 49% and as 42% in different documents.
- The pharmacodynamic evidence comes from a bradykinin challenge in 16 healthy volunteers receiving 12 or 22 mg, a surrogate used for icatibant dose selection, and the results were compared with published icatibant results.
- Safety was followed for 72 hours after a single dose.
- The results are reported in two posters described in a company press release and in the company's registration statement.

Source: [Pharvaris Form F-1/A registration statement (2021)](https://www.sec.gov/Archives/edgar/data/1830487/000119312521023578/d50231df1a.htm); [Lu et al. (2020)](https://ir.pharvaris.com/static-files/0361cd85-6000-490b-932b-d305e1f3ca1b); [Crabbé et al. (2021)](https://ir.pharvaris.com/static-files/a5937e81-635a-4808-b099-3a049c87c51b); [Derendorf et al. (2020)](https://ir.pharvaris.com/static-files/33217945-6893-4f49-8a93-c80ea6fb2a31); [Pharvaris ACAAI 2020 press release (2020)](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-presents-clinical-data-acaai-2020-demonstrating-safety)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
